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Mitocôndria, músculo estriado, envelhecimento, cancro, diabetes mellitus  
resumo 
 
O músculo-esquelético e o músculo cardíaco consomem diariamente grandes 
quantidades de ATP para a contração, pelo que não é de surpreender que a 
morfologia, a distribuição e a funcionalidade mitocondrial sejam importantes 
para a manutenção da sua homeostasia. Mais ainda, o músculo estriado 
apresenta duas populações de mitocôndrias, as intermiofibrilares (IMF), 
presentes em maior quantidade, e as subsarcolemais (SS). Na presente tese 
foram estudados, utilizando modelos animais, os mecanismos moleculares 
localizados na mitocôndria do músculo estriado para melhor compreender o 
papel da plasticidade mitocondrial em resposta a várias condições 
patofisiológicas nomeadamente o envelhecimento, a diabetes mellitus e o 
cancro. 
A análise bioquímica das populações de mitocôndrias isoladas do coração 
evidenciou uma maior atividade da cadeia respiratória nas mitocondriais IMF 
em comparação com as SS. A maior suscetibilidade das subunidades dos 
complexos da cadeia respiratória das mitocôndrias SS à carbonilação, mas 
não à nitração, parece justificar a menor atividade da cadeia respiratória 
observada nesta população de mitocôndrias.  
No estudo da adaptação mitocondrial ao envelhecimento verificou-se a 
acumulação de mitocôndrias disfuncionais no coração. A diminuição da 
atividade da cadeia respiratória parece ser justificada, pelo menos em parte, 
pelo aumento da suscetibilidade de proteínas mitocondriais a modificações 
oxidativas. Adicionalmente verificou-se que um estilo de vida sedentário tem 
um impacto negativo na funcionalidade mitocondrial do coração de animais 
idosos. 
No músculo-esquelético de animais com diabetes mellitus tipo 1 induzida pela 
administração de streptozotocina, verificou-se uma acumulação de 
mitocôndrias disfuncionais devido, pelo menos em parte, ao comprometimento 
do sistema de controlo de qualidade proteica mitocondrial. Efetivamente, a 
diminuição da atividade e da expressão de proteases AAA foi acompanhada 
pela acumulação de proteínas mitocondriais oxidadas.  
No músculo-esquelético de animais com caquexia associada ao carcinoma 
urotelial também se verificou a ocorrência de disfunção mitocondrial associada 
ao comprometimento do sistema de controlo de qualidade proteica, 
envolvendo as proteases mitocondriais paraplegina e Lon, com consequente 
acumulação de proteínas mitocondriais oxidadas. A disfunção mitocondrial 
observada no músculo gastrocnemius de animais com cancro ocorreu em 
paralelo com o aumento do catabolismo muscular e consequente perda de 
massa corporal. 
No global, os resultados sugerem que independentemente do estímulo 
patofisiológico que promove uma resposta adaptativa da mitocôndria no 
músculo estriado existem semelhanças no padrão de plasticidade mitocondrial. 
A redução da capacidade de produção de ATP parece ser devida ao aumento 
dos danos oxidativos das proteínas mitocondriais, nomeadamente das 
subunidades dos complexos da cadeia respiratória, de proteínas metabólicas e 
da MnSOD com consequente comprometimento das vias moleculares em que 
estão envolvidas. Os nossos resultados evidenciaram, pela primeira vez, a 
contribuição da disfunção do sistema de controlo de qualidade proteica 
mitocondrial para a acumulação de proteínas oxidadas e, consequentemente, 
para a disfunção mitocondrial.  
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abstract 
 
Both skeletal and cardiac muscles daily burn tremendous amounts of ATP to 
meet the energy requirements for contraction. So, it is not surprising that the 
maintenance of mitochondrial morphology, number, distribution and 
functionality in striated muscle are important for muscle homeostasis. In these 
tissues mitochondria present the added dimension of two populations, the 
intermyofibrillar (IMF) and the subsarcolemmal (SS) mitochondria, being IMF 
the most abundant one. In the present thesis, the molecular mechanisms 
harboured in mitochondria of striated muscles were studied using animal 
models, to better comprehend the role of mitochondrial plasticity in several 
pathophysiological conditions such as aging, diabetes mellitus and bladder 
cancer. 
The comparative analysis of IMF and SS populations isolated from heart 
evidenced a higher respiratory chain activity of mitochondria interspersed in the 
contractile apparatus. The higher susceptible of SS respiratory chain 
complexes subunits to carbonylation, but not to nitration, seems to justify the 
lower respiratory chain activity observed in this mitochondrial population. 
Our results showed that in heart from aged mice there is an accumulation of 
dysfunctional mitochondria. The age-related decrease of oxidative 
phosphorylation activity seems to be justified, at least partially, by the increased 
proneness of mitochondrial proteins as OXPHOS subunits and MnSOD to 
oxidative modifications. Moreover, a sedentary lifestyle seems to worsen the 
functional consequences of aging in heart by increasing mitochondrial proteins 
susceptibility to nitration.  
In skeletal muscle from rats with type 1 diabetes mellitus induced by 
streptozotocin administration, we verified the accumulation of dysfunctional 
mitochondria due, at least in part, to the impairment of PQC system. Indeed, 
the decreased activity of AAA proteases was accompanied by the accumulation 
of oxidatively modified mitochondrial proteins with impact in respiratory chain 
activity.  
The diminishing of mitochondria activity also underlies cancer-induced muscle 
wasting. Indeed, using a rat model of chemically induced urothelial carcinoma 
we verified that the loss of gastrocnemius mass was related to mitochondrial 
dysfunction due to, at least partially, the down-regulation of PQC system 
involving the mitochondrial proteases paraplegin and Lon. PQC impairment 
resulted in the accumulation of oxidatively modified mitochondrial proteins. 
In overall, regardless the pathophysiological stimuli that promote mitochondrial 
alterations, there are similarities in the pattern of disease-related mitochondrial 
plasticity. The diminished capacity for ATP production in striated muscle seems 
to be due to increased oxidative damage of mitochondrial proteins, namely 
subunits of respiratory chain complexes, metabolic proteins and MnSOD. Our 
data highlighted, for the first time, the impact of mitochondrial PQC system 
impairment in the accumulation of oxidized proteins, exacerbating the 
dysfunction of this organelle in striated muscle in several pathophysiological 
conditions. 
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3 
1. General Introduction 
 
Mitochondria are crucial organelles involved in energy production, metabolism and 
intracellular signaling (Benard and Rossignol 2008). These organelles vary in shape, 
number and activity to regulate several cellular physiological processes, like ATP 
production, redox status and calcium homeostasis. Both skeletal and cardiac muscles are 
extremely energy demanding tissues, highly reliant on mitochondrial oxidative metabolism 
(Sandri 2008). These muscles rapidly respond to metabolic challenges like exercise, 
inactivity or disease, being morphological, biochemical and functional alterations of 
mitochondria key factors in cellular metabolic adaptation. This mitochondrial remodeling 
is generally designated as “mitochondrial plasticity”, which is defined as changes of this 
organelle activity, content or oxidative phosphorylation capacity due to altered metabolic 
conditions (Hoppeler and Fluck 2003; Pagel-Langenickel, Schwartz et al. 2007) induced 
by aging or diseases like diabetes mellitus and cancer. 
Studies in striated muscle present the added dimension of two distinct mitochondrial 
populations that exist as a dynamic network. Mitochondria differ in their subcellular 
localization, morphology and biochemical properties. Subsarcolemmal (SS) mitochondria 
are located just underneath the sarcolemma and have a large, lamellar shape. In contrast, 
the intermyofibrillar (IMF) mitochondria are smaller, more compact, and are located 
between the contractile filaments. These two spatially distinct mitochondrial populations 
possess precise functional and biochemical properties and respond differently to external 
stimuli. Whereas IMF mitochondria are mainly devoted to the energy supply of myosin 
and SR-ATPases, SS mitochondria support other processes such as ion homeostasis or 
signaling pathways (Palmer, Tandler et al. 1977; Hoppeler 1986; Hoppeler and Fluck 
2003; Riva, Tandler et al. 2005; Hoppel, Tandler et al. 2009). 
Impairment of mitochondrial plasticity in striated muscle has been observed in various 
disorders, including diabetes mellitus, cancer as well as aging (Cohen 1995; Mahgoub and 
Abd-Elfattah 1998; Hayat, Patel et al. 2004; Boudina and Abel 2007). Underlying these 
pathophysiological conditions it has been reported changes in mitochondrial morphology, 
number, distribution and function (Hoppeler and Fluck 2003; Pagel-Langenickel, Schwartz 
et al. 2007). Mitochondrial dysfunction is usually related to enhanced oxidative stress 
(Raha and Robinson 2000), oxidative damage of biomolecules, decreased activities of the 
Mitochondrial plasticity in pathophysiological conditions 
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electron transport chain (ETC) complexes (Mandavilli, Santos et al. 2002) and decreased 
ability for ATP synthesis (Chang, Van Remmen et al. 2003). The accumulation of oxidized 
proteins in mitochondria is avoided by defense systems (Tatsuta and Langer 2008) as 
Protein Quality Control (PQC) system (Langer, Kaser et al. 2001; Voos and Rottgers 2002; 
Koppen and Langer 2007; Baker and Haynes 2011), which comprises a multitude of 
complexes that, among other roles, are involved in the specific proteolytic removal of 
terminally damaged polypeptides. However, in many pathophysiologic conditions PQC 
system is defective or overwhelmed (Koppen and Langer 2007). Either the case, the net 
result is mitochondrial dysfunction. So, PQC players might be seen as potential therapeutic 
targets to restore mitochondria functionality in pathophysiological conditions.  
Generally, it seems that mitochondrial plasticity is a key element in striated muscle 
adaptation under stress. In such conditions, the molecular mechanisms underlying 
mitochondrial plasticity might be overcome, explaining why mitochondrial dysfunction is 
an early event in the pathogenesis of diseases as for example diabetes mellitus (Ferreira et 
al., 2013). Despite the importance of mitochondrial plasticity in cell fate, its role as a 
determinant of cell viability is yet poorly understood.  
2. State of the art 
 
2.1. Mitochondria in striated muscle 
 
Mitochondria play critical roles in both life and death of striated muscle. This organelle not 
only produce ATP via oxidative phosphorylation for tissue survival and functionality, but 
also is involved in multiple cell signalling cascades and in the regulation of cellular 
metabolism, development, ion homeostasis and apoptosis (Benard, Faustin et al. 2006; 
Logan 2006; Benard and Rossignol 2008; Nunnari and Suomalainen 2012). Figure 1 
summarizes the metabolic pathways harbored in mitochondria, the regulatory mechanisms 
of protein import, apoptosis, proteolysis, redox, and of calcium levels.   
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Figure 1: Overview of mitochondria-related processes.  
A schematic cross-section of a mitochondrion is shown, with the proteins and protein complexes 
that are involved in various cellular pathways and processes. Mitochondrial pathways responsible 
for crucial cellular functions within cell, including protein import, OXPHOS, TCA cycle, β-
oxidation, apoptosis, proteolysis, redox and calcium regulation are detailed.  
VDAC, voltage-dependent anion exchanger; ANT, adenine nucleotide exchanger; TOMs, 
translocases of the outer membrane; TIMs, translocase of the inner membrane; Cyto C, cytochrome 
c; AIF, apoptosis-induced factor; UCP, uncoupling protein; i-AAA, proteases of the AAA family in 
the inner membrane; m-AAA, proteases of the AAA family in the matrix; GSSG, glutathione 
disulfide; GSH, glutathione; ClpXP, ATP-dependent Clp protease ATP-binding subunit clpX-like; 
MCU, mitochondrial calcium uniporter, PDH, pyruvate dehydrogenase; C-I, respiratory chain 
complex I; C-II, complex II; C-III, complex III; C-IV, complex IV; C-V, complex V; NADH, 
nicotinamide adenine dinucleotide;  FADH2- flavin adenine dinucleotide; SOD- superoxide 
dismutase, CPT1, Carnitine palmitoyltransferase I, CPT2, Carnitine palmitoyltransferase II; MISPI, 
mitochondrial intermembrane space protease (adapted from Zhang, Lin et al. 2012). 
 
Mitochondria are highly dynamic, pleomorphic organelles which fuse and divide in 
response to environment stimuli, development status, and energy requirement of the cell 
(Chan 2006; Frazier, Kiu et al. 2006; Campello and Scorrano 2010). Some authors argue 
that in most cells, mitochondria form a reticular network that radiate from the nucleus, 
creating an interconnected system that supplies the cell with energy and essential 
metabolites (Liesa, Palacin et al. 2009; Westermann 2010). Nevertheless, electron 
microscopy of mitochondrion defined their basic morphology as double-membrane 
organelle, typically rod-shaped and about 1-2 μm in length and 0.1-0.5 μm in width 
(reviewed by Logan 2006), presenting an outer membrane (OM) and an inner membrane 
(IM) with folded cristae that give rise to two aqueous compartments, the intermembrane 
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space (IMS) and the matrix (Duchen 2004; Logan 2006; Navarro and Boveris 2007; 
Benard and Rossignol 2008; Stowe and Camara 2009), as represented in figure 1. The OM 
surrounds the organelle, whereas the IM surrounds the central matrix space. The IMS is 
located between two membranes. The OM is relatively permeable to small molecules and 
ion species (Duchen 2004; Navarro and Boveris 2007), which move through 
transmembrane channels formed by a family of integral membrane proteins called porins. 
The microenvironment space that comprises IMS contains a distinct group of proteins 
which play major roles in cell physiology, in mitochondrial energetics and in cell death. 
The IM is largely impermeable and forms the barrier between the cytosol and the 
mitochondrial matrix. It is composed of segments of inner boundary membrane, parallel to 
the OM, that join the cristae at cristae junctions. The cristae contain the ETC and 
phosphorylation apparatus, and several membrane transporters (Lesnefsky, Moghaddas et 
al. 2001; Gilkerson, Selker et al. 2003; Duchen 2004; Logan 2006). The structure and 
number of cristae seem to vary enormously between different tissues (Duchen 2004), and 
seem dependent of the metabolic state of the tissue (Logan 2006; Stowe and Camara 
2009). For instance, mitochondria from heart muscle have more cristae than those from 
liver (Distler, Kerner et al. 2008). These differences occur to fulfill the distinct ATP 
demands of different cell types. The matrix is considered a highly functional zone of 
mitochondria once it harbors several metabolic pathways as Krebs cycle (Krebs 1940). 
Mitochondrial matrix also contains mitochondrial DNA, RNA and ribosome special 
carriers (Distler, Kerner et al. 2008). 
 
The mammalian mitochondrion contains 4 to 5 copies of its own circular DNA molecule 
(mtDNA). This small molecule of 16 kb encodes for 37 genes, from which 13 are proteins, 
all belonging to the respiratory chain (seven proteins from complex I, one from complex 3, 
three from complex IV, and two from complex V), 2 are rRNA (16S and 12S) and the 
remainder are mitochondrial tRNAs) (Wallace, Brown et al. 1999; Duchen 2004). mtDNA 
is traditionally considered “naked” due to the lack of histones and therefore less protected 
from oxidative damage than nuclear DNA (Duchen 2004). The mtDNA has a significant 
contribution for mitochondrial function and integrity (Joseph, Rungi et al. 2004; Zeviani 
and Di Donato 2004). Defects in the synthesis of one of the 13 mtDNA-encoded 
respiratory subunits can lead to respiratory chain dysfunction and to a wide range of 
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pathogenic conditions, some of which affect skeletal and cardiac muscles. Although 
mitochondria contain their own genome and protein synthesizing machinery they are only 
semi-autonomous (Logan 2006). Proteomic cataloguing studies estimated that 
mitochondria contain about 1000 (yeast) to 1500 (human) different proteins (Sickmann, 
Reinders et al. 2003; Perocchi, Jensen et al. 2006; Reinders, Zahedi et al. 2006; Pagliarini, 
Calvo et al. 2008) with the vast majority (~98%) encoded within the nucleus (synthesized 
upon cytosolic ribosomes and imported to mitochondria by an elaborate network of 
translocases and sorting machineries) (Koehler 2000; Neupert and Herrmann 2007; Ryan 
and Hoogenraad 2007; Chacinska, Koehler et al. 2009). Therefore, the mitochondrial 
proteome should be viewed as a dynamic program generated by a cross-talk between the 
two genomes and able to adapt to tissue needs or disease states (Poyton and McEwen 
1996; Ryan and Hoogenraad 2007; Dimmer and Rapaport 2008). Changes in the 
mitochondrial proteome exert influences over mitochondrial homeostasis, underlying 
diseases and controlling natural processes as development and aging (Wallace 1999; 
Duchen 2004; Lowell and Shulman 2005). 
 
 
Mitochondria are highly plastic in terms of shape, number and distribution between tissues 
and cells types (Yaffe 1999; Logan 2006; Vafai and Mootha 2012). The number of 
mitochondria per cell is variable, depending on cell type and pathophysiological state 
(Logan 2006; Stowe and Camara 2009; Zick, Rabl et al. 2009; Vafai and Mootha 2012). 
Tissues with highly energetic demands have great number of mitochondria (Duchen 2004; 
Vafai and Mootha 2012). Liver cells have 1000–2000 mitochondria per cell, making up 
20% of the cell volume, and the IM (cristae) area is about 5 times greater than that of the 
OM. In cardiac mitochondria, the cristae area is much larger, and the mitochondrial 
volume can reach 30% of cell volume (Stowe and Camara 2009). Indeed, the mammalian 
heart is a hotspot of metabolic activity, consuming each day 100 times its own weight in 
ATP (Dorn 2013). Striated muscles are highly reliant on mitochondria and skeletal muscle 
accounts for approximately 40% of total body mass, being a major site of metabolic 
activity (Romanello and Sandri 2013). In striated muscles there are two distinct 
populations of mitochondria that exist as a dynamic network. Mitochondria differ in their 
subcellular localization, morphology and biochemical properties and they constantly adapt 
to cellular needs. SS mitochondria are located just beneath the sarcolemma whereas the 
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smaller IMF mitochondria, which account for 80% of mitochondria, is interspersed in the 
contractile filaments (Palmer, Tandler et al. 1977; Hoppeler 1986; Hoppeler and Fluck 
2003; Riva, Tandler et al. 2005; Hoppel, Tandler et al. 2009). It has been suggested that SS 
mitochondria provide energy for membrane-related events like signalling and transport of 
ions and others subtracts, while IMF mitochondria supply ATP for the interaction of 
myosin with actin leading to muscle contraction (Romanello and Sandri 2013). The two 
populations differ in structure, size, ATP levels, protein import rates, substrate utilization, 
and other biochemical properties. IMF mitochondria have a higher rate of oxygen 
consumption, ATP content, protein import rates, and enzyme activities when compared 
with SS mitochondria (Palmer, Tandler et al. 1977; Cogswell, Stevens et al. 1993; 
Takahashi and Hood 1996). In cardiac muscle the specific activity of many mitochondrial 
enzymes like succinate dehydrogenase and citrate synthase is greater in IMF than in SS 
mitochondria (Palmer, Tandler et al. 1977). In the cardiac muscle, the rate of oxidative 
phosphorylation is 1.5 times higher in IMF mitochondria (Palmer, Tandler et al. 1977), 
supporting the ATP needs for muscle contraction (Ferreira, Vitorino et al. 2012). In 
skeletal muscle, state 3 respiration (ADP-stimulated respiration) is 2.3- to 2.8-fold greater 
in IMF than in SS mitochondria and IMF mitochondria show 3 fold greater ATP synthesis 
rates, indicating that SS and IMF mitochondria have distinct energetic characteristics. 
Besides bioenergetic differences, cardiac mitochondria populations have different cristae 
morphology. SS mitochondria present lamelliform cristae whereas in IMF mitochondria 
predominates tubular cristae (Riva, Tandler et al. 2005), which might reflect compositional 
differences between mitochondria populations. In skeletal muscle endogenous 
mitochondrial protein synthesis is 1.8-fold higher in IMF than in SS mitochondria. 
Moreover, IMF mitochondria have 3–4-fold greater protein import rates of the precursor 
malate dehydrogenase and ornithine-carbamoyltransferase than SS (Takahashi and Hood 
1996). Higher amounts of mitofilin, the mitochondrial-associated protein involved in the 
regulation of cristae morphology, were observed in IMF mitochondria compared to SS, 
being more pronounced in cardiac tissue than in gastrocnemius muscle (Ferreira, Vitorino 
et al. 2012). Furthermore, the two mitochondrial subpopulations respond differently to 
distinct metabolic challenges, including exercise (Krieger, Tate et al. 1980), aging (Fannin, 
Lesnefsky et al. 1999; Suh, Heath et al. 2003; Ljubicic, Joseph et al. 2009), obesity and 
type 2 diabetes (Ritov, Menshikova et al. 2005), fasting (Lionetti, Mollica et al. 2007), and 
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apoptosis (Adhihetty, Ljubicic et al. 2007). Cardiac SS mitochondria seem to be more 
prone to ischemia damage, due to an increased loss of cardiolipin, reduced oxidative 
phosphorylation and reactive oxygen species (ROS) production (Lesnefsky, Slabe et al. 
2001). In contrast, cardiac IMF mitochondria seem to be more susceptibility to aging and 
heart failure due to increased oxidative stress (Rosca, Minkler et al. 2011). However, there 
is no consensus on the functional identity of SS and IMF mitochondria and on the 
significance of the differential response to pathophysiologic stimuli. 
2.1.1. Mitochondrial oxidative phosphorylation system 
 
Mitochondria have a key role in cellular metabolism, harboring the enzymatic reactions 
underlying the metabolism of carbohydrates, fats and proteins, which intermediate 
metabolites are selectively imported into the mitochondrial matrix and further metabolized 
into nicotinamide adenine dinucleotide (NADH) and/or flavin adenine dinucleotide 
(FADH2). The electrons released by the oxidation of NADH and FADH2 are transferred 
via the ETC to the final electron acceptor molecular oxygen, which is reduced to water 
(Poyton and McEwen 1996; Benard and Rossignol 2008; Huttemann, Lee et al. 2008). 
ETC consists in four major multi-subunit complexes (complexes I-IV), which are localized 
in the IM. ETC also involves two electron transport carriers: ubiquinone or coenzyme Q10, 
embedded in the membrane lipid bilayer, and cytochrome c, localized on the external 
surface of the IM (Poyton and McEwen 1996; Benard and Rossignol 2008). Together with 
a fifth complex, the ATP synthase (complex V), they are responsible for the production of 
energy to the cell in the form of ATP and constitute the mitochondrial oxidative 
phosphorylation (OXPHOS) (Benard and Rossignol 2008). The complexes that establish 
the ETC are multi-subunits protein complexes associated with prosthetic groups that allow 
the electrons to flow. Interestingly, the proteins from complex II are entirely encoded by 
the nucleus, while all the other complexes represent a mixture of proteins encoded by 
nuclear and mitochondrial DNA (Benard and Rossignol 2008).  
Complex I (NADH-ubiquinone oxidoreductase; NADH dehydrogenase) is the largest 
respiratory complex, with a molecular mass greater than 1000 kDa, and in heart of bovine 
comprises 46 different subunit peptides, including flavin mononucleotide (FMN) moiety 
and seven to nine iron-sulfur centers (FeS) and up to three detectable ubisemiquinone 
species. These complexes catalyze the oxidation of NADH to NAD
+
, transferring two 
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electrons to ubiquinone. This process is coupled to the translocation of four protons across 
the membrane out mitochondria matrix. Complex I has a L-shaped form, with a long 
hydrophobic arm and a short hydrophilic arm with the FMN and the NADH active centers 
that extends the protein complex into the matrix, (Janssen, Nijtmans et al. 2006; Navarro 
and Boveris 2007).  
Complex II (succinate dehydrogenase; succinate-ubiquinone reductase) is a 
succinate:ubiquinone oxidoreductase that reduces succinate to fumarate, transferring two 
electrons to ubiquinone. This complex is simultaneously part of the ETC and TCA cycle. 
In eukaryotes this oligomeric complex is composed of 4 subunits namely a flavoprotein, 
with a FAD molecule covalently bound, an iron-sulfur protein and two hydrophobic 
smaller peptides that serve as membrane anchors (Cecchini 2003; Navarro and Boveris 
2007; Rutter, Winge et al. 2010). Succinate dehydrogenase is the only respiratory complex 
that does not pump protons across the IM during its catalytic cycle (Dudkina, Sunderhaus 
et al. 2008; Rutter, Winge et al. 2010). The mobile carrier between complex I/complex II 
and complex III is a lipid soluble benzoquinone with a long isoprenoid side chain that may 
exist in three oxidation states: ubiquinone – fully oxidized, semiquinone – semi-oxidized, 
or ubiquinol – fully reduced. The most common form in mammals has 10 isoprene units 
and is referred as Coenzyme Q10 (Navarro and Boveris 2007). 
Complex III (cytochrome bc1 complex; ubiquinol-cytochrome c oxidoreductase) is a 
multisubunit integral membrane complex of the mitochondrial transport chain, which 
catalyzes electron transfer from ubiquinol to cytochrome c and couples this process to 
electrogenic translocation of protons across the IM (Brandt and Trumpower 1994; Berry, 
Guergova-Kuras et al. 2000). This complex in mammalian is composed by 11 
polypeptides, 3 of which are associated with the redox centers b562, b566 and c1 heme and an 
iron-sulfur cluster (Cecchini 2003). The membrane spanning region of complex III consists 
of 13 transmembrane helices, eight of which belong to cytochrome b. Cytochrome c (cyt c) 
is a small peptide bound to a heme c group that is associated to the IM, facing the IMS. It 
is reduced by the electrons transferred from complex III, transporting them to complex IV 
(Navarro and Boveris 2007; Lenaz and Genova 2009).  
Complex IV (cytochrome c oxidase, cytochrome oxidase; ferrocytochrome c: oxygen 
oxidoreductase) is the final catalyst of the ETC, being located in the inner mitochondrial 
membrane (Diaz, Fukui et al. 2006). This 200 kDa multicomponent protein reduces O2 to 
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H2O, consuming four protons from the matrix (Navarro and Boveris 2007; Fontanesi, Soto 
et al. 2008). The enzyme in mammalian contains 13 different subunits, 3 of which are 
mitochondrially encoded (Cecchini 2003). The redox centers of complex IV are two heme 
a centres, heme a and heme a3, located in two different environments, each one associated 
to a copper atom, respectively, CuA and CuB (Navarro and Boveris 2007). 
The electrochemical gradient of protons generated by the pumping activity of complexes I, 
III and IV is used by ATP synthase to synthesize ATP from ADP and phosphate, which is 
coupled to the backflow of protons to the matrix (Huttemann, Lee et al. 2008). Most of the 
cellular ATP of eukaryote cells is synthesized by the F1F0-ATPase complex present in the 
mitochondrial inner membrane during oxidative phosphorylation. Mitochondrial ATP 
synthase, F1-F0-ATPase or complex V is formed by 15-18 distinct subunits. It is 
composed of two distinct functionally and physically components: F1, peripheral to 
membrane, and F0, integral at the inner membrane (Weber 2006; Fontanesi, Soto et al. 
2008). 
 
The organization of the OXPHOS system within the IM appears to be far more 
complicated than previously thought. There are two main explanations for the interactions 
between complexes: the fluid state and the solid state models. The fluid state organization 
model supports that electron transport through the ETC was thought to occur through 
random interactions of individual protein complexes and the mobile carriers coenzyme Q 
and cyt c in the IM. This model is based on the finding that all individual protein 
complexes of the OXPHOS system can be purified in enzymatically active form and on 
lipid dilution experiments (Acin-Perez, Fernandez-Silva et al. 2008; Schon and Dencher 
2009). More recently, this model was confronted with an alternative view, the solid state in 
which individual complexes are physically grouped into supercomplexes within the IM 
that transport electrons more efficiently (Lenaz and Genova 2007). Schagger (2001) found 
structural evidences of specific OXPHOS complexes associations in yeast and mammalian 
mitochondria using Blue-Native electrophoresis (BN-PAGE), and so introduced the model 
of the “respirasome”, confirming earlier observations favoring specific inter-complex 
interactions (Schagger and von Jagow 1991; Schagger 2001). However, OXPHOS 
supercomplexes and individual OXPHOS complexes co-exist within the IM into a dynamic 
process that depends on the physiological state (Dudkina, Sunderhaus et al. 2008). Indeed, 
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such associations may promote stability and substrate channeling while minimizing ROS 
formation (Shoubridge 2012). 
2.1.2. Mitochondrial oxidative stress 
 
In addition to ATP production for cell survival, the mitochondria are also a major source of 
ROS/RONS. Normally, up to 5% of the oxygen consumed by the mitochondrial respiratory 
chain undergoes one electron reduction, typically at complexes I, II or III, generating 
superoxide (O2
•-
) and hydroxyl (HO
•
) radicals, and hydrogen peroxide (H2O2) (Kirkinezos 
and Moraes 2001; Turrens 2003; Muller, Liu et al. 2004; Ott, Gogvadze et al. 2007; 
Murphy 2009). Superoxide can also react with nitric oxide (NO
•
) to form peroxynitrite 
(ONOO
−
). These metabolic by-products have important physiological functions (e.g. 
inflammation) but might also be powerful cell-damaging oxidants, though can be 
neutralized by antioxidant enzymes, as manganase superoxide dismutase (MnSOD) and 
glutathione peroxidase (GPx) (Ott, Gogvadze et al. 2007). In recent years, there is 
increasing evidence that ROS are not only toxic but also needed for healthy life (Veal, Day 
et al. 2007; Brigelius-Flohe 2009; Hamanaka and Chandel 2010; Bae, Oh et al. 2011; Sena 
and Chandel 2012) (Figure 2). Controlled produced ROS act as a secondary messenger 
amplifying signals that are crucial for normal cell function (cell proliferation and 
differentiation). An induction of ROS production will lead to adaptative programs 
including the transcriptional upregulation of antioxidant genes. In contrast, an overt 
imbalance between ROS production and the antioxidant defense systems leads to the 
breakage of normal homeostasis (oxidative stress) and will signal the initiation of the 
senescence and apoptosis. Non-signaling, irreversible damage to cellular components (e.g. 
proteins, nucleic acids, and lipids) is only observed under the highest levels of cellular 
ROS and are closely related to a wide range of pathophysiogical conditions, such as 
cancer, cardiovascular diseases, aging, diabetes mellitus and neurodegenerative diseases 
(Hamanaka and Chandel 2010; Bae, Oh et al. 2011; Verdejo, del Campo et al. 2012). 
Therefore, mitochondria can be seen as a main source of ROS production under 
pathophysiological conditions as well as primary target of its damaging effects (Turrens 
2003). 
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Figure 2: Mitochondrial ROS levels are crucial for cellular signaling.  
Low levels of mitochondrial ROS are required for cellular processes such as proliferation and 
differentiation. An induction in ROS production will lead to adaptive programs including the 
transcriptional up-regulation of antioxidant genes. Higher levels of ROS will signal the initiation of 
senescence and apoptosis. Non-signaling, irreversible damage to cellular components is only 
observed under the highest levels of cellular ROS (adapted from Hamanaka and Chandel 2010). 
 
ROS signaling contributes to muscle homeostasis, maintaining normal striated muscle 
structure and function (Droge 2002; Smith and Reid 2006; Brigelius-Flohe 2009; Musaro, 
Fulle et al. 2010). ROS levels augment in response to both increased contractile activity 
(i.e. muscular exercise) and prolonged periods of muscle disuse (e.g. immobilization). 
These seemingly contradictory signaling functions of ROS are probably due to differences 
in both the magnitude and the temporal pattern of ROS generation. For example, a 
moderate increase in skeletal muscle ROS production during a short time period (e.g. 
minutes) can activate signaling pathways leading to cellular adaptation and protection 
against future stresses (Powers and Jackson 2008; Jackson 2009; Ristow, Zarse et al. 2009; 
Silva, Pinho et al. 2009; Strobel, Peake et al. 2011). In contrast, high levels of ROS over 
long time periods (e.g. hours) may result in chronic activation of signaling pathways that 
promote proteolysis and potentially cell death (Sastre, Asensi et al. 1992; Vina, Gimeno et 
al. 2000; Palazzetti, Richard et al. 2003; Ji, Gomez-Cabrera et al. 2006; Silva, Pinho et al. 
2009) but also positive adaptations following moderate exercise (Ristow, Zarse et al. 
2009). 
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2.1.3. Mitochondrial protein quality control system  
 
Mitochondria integrity and function are regulated by defense processes (Tatsuta and 
Langer 2008), being the PQC system the major biochemical process that contributes to the 
maintenance of cellular functions under normal and stress conditions (Langer, Kaser et al. 
2001; Voos and Rottgers 2002; Koppen and Langer 2007; Baker and Haynes 2011). In 
general, PQC comprises a multitude of complexes and interdependent biochemical 
reactions that contribute to the functional integrity of proteins, ranging from the support of 
protein (re)folding, the protection against aggregation to the specific proteolytic removal of 
terminally damaged polypeptides. PQC proteins are activated by the accumulation of 
misfolded proteins within mitochondria in order to balance the homeostasis (Baker and 
Haynes 2011).  
PQC comprises two major pathways that avoid irreversible protein aggregation. Firstly, 
chaperones (Hsp60, Hsp70 and Hsp100 families) recognize misfolded proteins, bind and 
try to refold them into their native form thus reconstituting protein function. However, if 
refolding fails to occur, proteases of the AAA family (ATPases associated with a variety of 
cellular activities) eliminate misfolded proteins by degrading them into small fragments 
and amino acids, which are transported out of mitochondria and are then available for de 
novo protein synthesis in the cytoplasm (Langer, Kaser et al. 2001; Goldberg 2003; Voos 
2009; Luce, Weil et al. 2010; Baker and Haynes 2011; Sauer and Baker 2011; Lionaki and 
Tavernarakis 2013). AAA
+
 proteins convert the energy derived from ATP hydrolysis into 
mechanical work and mediate remodeling of macromolecular structures, thereby 
controlling a variety of cellular processes (Tatsuta and Langer 2009). During organelle 
biogenesis and in stress conditions, unfolded or misfolded proteins can accumulate in each 
compartment of mitochondria, and so compartment-specific PQC machinery is needed to 
prevent protein aggregation (Baker and Haynes 2011) (Figure 3).  
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Figure 3:  Protein quality control system monitors the four mitochondrial compartments.   
Localized quality control proteases monitor and protect all mitochondrial compartments against 
deleterious accumulation of misfolded, misassembled or unfolded proteins. The inner membrane 
contains two proteases, each oriented with its respective catalytic site facing the matrix or 
intermembranar space side of the membrane. The m-AAA has a hetero-oligomeric assembly 
composed of paraplegin and AFG3L2 and i-AAA has homo-oligomeric assembly composed of 
YME1L1. The matrix is monitored by two different AAA proteases, ClpXP and Lon, whereas the 
intermembranar space is monitored by HtrA2 (Omi). The rhomboid protease PARL resides in the 
IM where it is involved in intramembrane proteolysis of substrates including PINK1. Less is 
known about protein QC of the mitochondrial OM or protein import into the organelle, but the 
cytosol-localized ubiquitin–proteasome system is probably involved (adapted fromBaker and 
Haynes 2011). 
PARL, Presenilins-associated rhomboid-like protein; ClpXP, ATP-dependent Clp protease ATP-
binding subunit clpX-like ;  HtrA2(Omi); m-AAA, matrix-ATPase associated with various cellular 
activities; i-AAA, intermembranar space-ATPase associated with various cellular activities; 
YME1L1, yeast mitochondrial escape protein-1 like 1; IMS- intermembranar space; AFG3L2, ATP 
family gene 3-like 2. 
 
The inner mitochondrial membrane is the protein-richest cellular membrane and contains 
the OXPHOS, which homeostasis is of major importance to maintain mitochondrial 
function. The membrane-bound ATP-dependent proteases, AAA proteases, mediate the 
proteolytic breakdown of membrane proteins. Two AAA proteases, which expose their 
catalytic sites to opposite membrane surfaces, are apparently ubiquitously present in the 
inner membrane: the i-AAA protease active in the intermembrane space and m-AAA 
protease in the matrix. (Kaser and Langer 2000; Koppen and Langer 2007; Baker and 
Haynes 2011). Both of these proteases mediate the ATP-dependent dislocation of substrate 
proteins from the membrane allowing their degradation in a hydrophilic environment 
(Leonhard, Guiard et al. 2000). The i-AAA protease complex is a homo-oligomeric formed 
by six subunits of the Yeast Mitochondrial Escape protein-1-Like 1 (YME1L1) (Leonhard, 
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Herrmann et al. 1996). In human mitochondria, m-AAA can be organized in hetero- or 
homo-oligomeric assemblies composed of paraplegin and ATPase family gene 3-like 2 
(Afg312) and it is essential for the maintenance of oxidative phosphorylation (Kaser and 
Langer 2000; Tatsuta 2009). Within mitochondria, m-AAA proteases have versatile 
activities, being not only quality control enzymes that completely degrade non-assembled 
or misfolded polypeptides (Arlt, Tauer et al. 1996), but can also act as processing enzymes 
specifically cleaving mitochondrial proteins with regulatory functions, having a chaperone-
like activity (Koppen and Langer 2007; Koppen, Bonn et al. 2009). 
Paraplegin is a subunit of the hetero-oligomeric m-AAA protease, localized in the inner 
mitochondrial membrane, with the active site in the mitochondrial matrix (Gerdes, Tatsuta 
et al. 2012; Rugarli and Langer 2012). Paraplegin has three domains, one of which has an 
AAA+ module, making this protease part of the AAA+ superfamily (Karlberg, van den 
Berg et al. 2009). This protein forms cylindrical hetero-hexamers to become active, a 
known feature from AAA+ proteins family (Karata, Inagawa et al. 1999). The m-AAA 
protein complex is both responsible for PQC in the IM and protein activation, and 
specifically, paraplegin is involved in the degradation of misfolded proteins, cleavage of 
mitochondrial targeting sequences, mitochondrial ribosome maturation (Nolden, Ehses et 
al. 2005) and is also linked to the proteolytic processing of OPA1, a GTPase in the IM, 
which alteration cause optical atrophy (Ishihara, Fujita et al. 2006). In addition to its 
function in PQC, the m-AAA proteases control the biogenesis of the OXPHOS complexes. 
A nuclear encoded subunit of mitochondrial ribosome, MrpL32, is matured by m-AAA 
proteases, having in this case the role of processing this ribosomal subunit and not of a 
PQC enzyme (Nolden, Ehses et al. 2005). Being MrpL32 processing a prerequisite for its 
assembly into ribosomes and mitochondrial translation, the m-AAA protease directly 
regulates the synthesis of mtDNA-encoded OXPHOS subunits within mitochondria 
(Tatsuta and Langer 2008). It is important to note that both regulatory and PQC functions 
of the m-AAA protease are interdependent and may compete with each other. While m-
AAA degrades substrates resultant from aging and ROS production, it will not assemble 
MrpL32, resulting in the inhibition of OXPHOS proteins translation (Nolden, Ehses et al. 
2005). The m-AAA protease also presents a protective function regarding OXPHOS 
complexes, mediating the maturation of the ROS scavenger cytochrome c peroxidase 
(Ccp1) in the mitochondrial intermembrane space. This peroxidase is processed by the m-
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AAA protease and the rhomboid protease Pcp1, an intramembrane-cleaving peptidase in 
the inner membrane (Esser, Tursun et al. 2002). Two different ATP-dependent proteases 
have been identified in the matrix, the Lon/Pim1 protease (Suzuki, Suda et al. 1994; Van 
Dyck, Pearce et al. 1994) and the ClpXP protease (de Sagarra, Mayo et al. 1999; Santagata, 
Bhattacharyya et al. 1999). While the Lon protease contains proteolytic and ATPase 
activities on the same polypeptide, the ClpP protease has to form a protein complex with 
the mitochondrial ClpX chaperone that provides ATPase activity and is responsible for 
substrate recognition (Santagata, Bhattacharyya et al. 1999; Kang, Ortega et al. 2002). 
Besides the requirement of mitochondrial ClpXP in the unfolded protein response, its role 
within mitochondria is still poorly comprehended (Zhao, Wang et al. 2002; Haynes, 
Petrova et al. 2007). Lon is a serine protease that forms soluble heptameric complexes in 
the MM (Stahlberg, Kutejova et al. 1999) and has been demonstrated to mediate the 
proteolysis of misfolded and unassembled matrix proteins (Bota, Van Remmen et al. 
2002). Lon is involved in the removal of damaged proteins including oxidized proteins, 
and thereby prevents the extensive accumulation of protein aggregates (Bota, Van 
Remmen et al. 2002; Bota, Ngo et al. 2005). Besides its role in protein quality control, 
studies in yeast suggest an essential function of Lon in mtDNA maintenance (Suzuki, Suda 
et al. 1994; Van Dyck, Pearce et al. 1994) and in organelle biogenesis and maintenance 
(Bender, Leidhold et al. 2010; Baker and Haynes 2011). In contrast to matrix and IM 
proteolysis, little is known about the turnover of proteins localized in the IMS and the OM. 
A putative candidate for the surveillance of protein quality in the IMS is HtrA2/Omi, a 
member of a conserved family of serine proteases. In mammals, HtrA2/Omi is up-
regulated in response to several stress stimuli (Faccio, Fusco et al. 2000; Gray, Ward et al. 
2000). In contradiction to a potential protective role, several studies proposed HtrA2/Omi 
to promote cell death (Suzuki, Imai et al. 2001; Hegde, Srinivasula et al. 2002; van Loo, 
van Gurp et al. 2002). Following apoptotic stimuli, HtrA2/Omi is released from 
mitochondria into the cytosol where it facilitates apoptosis through its protease activity. 
Preserving the integrity of proteins, biomolecules prone to molecular damage, is a 
fundamental function of all biological systems. Impaired quality control of mitochondria 
might contribute to the build-up of oxidized proteins and impairment of mitochondrial 
redox homeostasis associated to aging and various diseases, including prevalent 
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neurological disorders like Parkinson's disease and spinocerebellar ataxia (Koppen and 
Langer 2007; Rugarli and Langer 2012).  
2.2. The role of the post-translational modifications in the regulation of 
mitochondrial plasticity 
 
Mounting evidence suggests that post-translational modifications (PTMs) of mitochondrial 
proteins play an important role in organelle homeostasis and adaptation to biomechanical 
stressors. PTMs can be either narrowly restricted to rapid and reversible modifications (e.g. 
phosphorylation and acetylation), often mediated by specific enzymes, or broadly extended 
to include non-enzymatic processes such as carbonylation and nitration that might lead to 
protein oxidative damage and proteolysis, affecting protein levels, localization and/or 
function. Both types of PTMs are important to consider in pathophysiologic conditions, 
once the interplay between regulatory PTMs and the ones causal of mitochondrial 
dysfunction might modulate the extent of disease progression (Foster, Van Eyk et al. 2009; 
Kerner, Lee et al. 2011). Due to the regulatory role of PTMs (Grimsrud, Carson et al. 
2012; Sack 2012), recent studies have investigated its effects on striated muscle 
mitochondrial plasticity. 
Reversible phosphorylation and acetylation tightly regulate mitochondrial processes 
leading to energy production and synthesis of mitochondrially-encoded components of 
OXPHOS complexes (Aponte, Phillips et al. 2009; Balaban 2010; Guan and Xiong 2011). 
It is not surprising that altered levels of phosphorylation and acetylation have been linked 
to diseases, such as cancer, diabetes mellitus and aging (Cohen 2002). Reversible 
phosphorylation of proteins is the most common and one of the best understood signaling 
mechanisms that regulate and connect many metabolic pathways. Indeed, using ATP as 
substrate, kinases transfer phosphate groups to serine, threonine and tyrosine residues 
generating negatively charged side chains, which significantly impacts the structural 
properties of those amino acid residues (Koc and Koc 2012). With the recent advent of 
mass spectrometry-based technologies applied to the study of proteins’ phosphorylation, a 
new vision has emerged of an extensively phosphorylated and dynamically regulated 
mitochondrial proteome (Pagliarini and Dixon 2006; Agnetti, Kane et al. 2007). 
Mitochondrial phosphoproteome dynamics in cardiac (Boja, Phillips et al. 2009; Deng, 
Zhang et al. 2011; Phillips, Aponte et al. 2011) and in skeletal muscle (Zhao, Leon et al. 
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2011) is critically reviewed in Chapter III taking in consideration current data on protein 
phosphorylation profiling in mitochondria, the potential kinases involved and how 
pathophysiological conditions modulate the mitochondrial phosphoproteome.   
Reversible acetylation on the ε-amino group of internal lysine residues (hereinafter referred 
to as acetylation) has emerged as a PTM with a crucial role in regulating target protein 
functions, akin to phosphorylation. This modification neutralizes the positive charges of ε -
amino groups of lysine residues and usually result in the inhibition of metabolic enzymes 
activities (Fritz, Galligan et al. 2012), including the activities of glutamate dehydrogenase, 
long chain fatty acid dehydrogenase, and nuclear encoded subunits of the electron transport 
chain complexes, complexes I and II (Ahn, Kim et al. 2008; Cimen, Han et al. 2010; 
Finley, Haas et al. 2011). Over 20-30 % of all proteins in the mitochondria are acetylated, 
of which the majority are involved in metabolic pathways as fatty acid oxidation, amino 
acid oxidation, the TCA cycle, urea cycle, and oxidative phosphorylation (Bao and Sack 
2010; Fritz, Galligan et al. 2012; Koc and Koc 2012). Despite intensive studies aiming the 
identification of acetyltransferases in mammalian mitochondria, no protein 
acetyltransferase activity has been detected to date (Koc and Koc 2012). The regulation of 
acetylation is mediated by NAD
+
-dependent protein deacetylases called the Sirtuin (SIRT) 
family, being SIRT3 one of the most studied in the control of mitochondrial proteins 
deacetylation (Bao and Sack 2010; Fritz, Galligan et al. 2012). The mitochondrial sirtuins 
(SIRT3, SIRT4 and SIRT5) are vital for cell survival and act in a NAD
+
-dependent 
manner, using NAD
+
 as a co-substrate in deacetylation and ADP-ribosylation reactions 
(Verdin, Hirschey et al. 2010). SIRT3 has shown to be the major deacetylase that 
modulates mitochondrial functions in response to [NADH]/[NAD
+
] ratio by regulating the 
activities of several key metabolic enzymes while SIRT4 and SIRT5 have fewer known 
substrates in mammalian mitochondria (Lombard, Alt et al. 2007; Yang, Yang et al. 2007). 
In the absence of SIRT3, mitochondrial proteins become hyperacetylated, which impairs 
their function, contributing to mitochondrial dysfunction. SIRT3 expression was reported 
to decrease in mouse models of T2DM (Palacios, Carmona et al. 2009; Jing, Emanuelli et 
al. 2011). Moreover, SIRT3 appears to be regulated by exercise in skeletal muscle and by 
pressure overload in the heart (Sack 2011). Nevertheless, the regulatory role of protein 
lysine residues acetylation in the control of mitochondrial homeostasis is only beginning to 
be explored. 
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Since mitochondria is a major source of RONS, mitochondrial proteins are especially 
exposed to oxidative modifications, being the elimination of modified proteins crucial for 
the maintenance of this organelle’s integrity. Hence, the failure of functional protein 
maintenance and accumulation of oxidized proteins has been reported in several 
pathophysiological conditions. Post-translational oxidative modifications of proteins, 
manifested as carbonylation and nitration, appear to be a key mechanism underlying 
impaired functional and/or structural protein integrity leading to mitochondrial dysfunction 
(Turko, Li et al. 2003; Kanski, Behring et al. 2005; Choksi and Papaconstantinou 2008). 
Protein carbonylation has been subject of great interest, because it is irreversible and 
results in protein irreparable damage. This type of oxidative modification occurs when 
proteins directly react with ROS, leading to the formation of protein derivatives or peptide 
fragments containing highly reactive carbonyl groups, such as aldehydes and ketones 
(Dalle-Donne, Rossi et al. 2003; Stadtman and Levine 2003). Among the main carbonyl 
products of metal-catalyzed oxidation of proteins are glutamic and aminoadipic 
semialdehydes (Requena, Chao et al. 2001; Requena, Levine et al. 2003; Babusikova, 
Jesenak et al. 2008). Lysine, arginine, proline, and threonine residues of proteins are 
particularly sensitive to metal-catalyzed oxidation, leading in each case to the formation of 
carbonyl derivatives. Peptide carbonyl derivatives are also obtained as fragmentation 
products of peptide bond cleavage reactions or can be formed by the interaction of protein 
amino acid side chains (cysteine sulfhydryl groups, histidine imidazole groups, and lysine 
amino groups) with lipid peroxidation products, including 4-hydroxy-2-nonenal, acrolein, 
and malondialdehyde. Glycation/glycoxidation reactions can also lead directly to carbonyl 
adducts and indirectly to the formation of N-carboxymethyl-lysine derivatives that, 
because of their strong chelating ability, are able to promote the generation of carbonyl 
groups by metal-catalyzed reactions (Stadtman and Levine 2003; Stadtman 2006). Indeed, 
protein carbonyl content is actually the most general indicator and by far the most 
commonly used marker of protein oxidation, and accumulation of carbonylated proteins in 
mitochondria is undoubtedly associated with impaired respiratory function, playing a 
crucial role in the cellular response to pathophysiological stimuli (Feng, Xie et al. 2008; 
Alves, Vitorino et al. 2010).  
Protein tyrosine nitration is a covalent protein modification resulting from the addition of a 
nitro (-NO2) group onto one of the two equivalent ortho carbons of the aromatic ring of 
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tyrosine residues (Abello, Kerstjens et al. 2009). Many diseases are associated with 
increased levels of protein-bound nitrotyrosine, which has also been used as a marker of 
oxidative damage. Protein tyrosine nitration was reported in mitochondria of striated 
muscle in diabetes mellitus (Turko, Li et al. 2003; Dabkowski, Baseler et al. 2010; 
Ferreira, Guerra et al. 2013) and aging (Kanski, Behring et al. 2005). Although used as a 
marker of pathological disease processes and of oxidative stress, some authors argue that 
protein tyrosine nitration can be selective, dynamic and reversible and seems to fulfill the 
criteria of a regulatory physiological signal (Aulak, Koeck et al. 2004; Gow, Farkouh et al. 
2004; Yakovlev and Mikkelsen 2010). 
 
2.3. Mitochondrial plasticity of striated muscle in response to 
pathophysiological conditions 
 
Striated muscle daily burns tremendous amounts of ATP to meet the energy requirements 
for contraction. In this sense, it is not surprising that maintenance of mitochondrial 
morphology, number, distribution and function in cardiac and skeletal tissues are important 
to preserve muscle function (Romanello and Sandri 2013). In order to fulfill tissue’s needs, 
mitochondria have a considerable plasticity, responding rapidly and adequately when 
challenged by physiological or pathological stimuli. Mitochondrial plasticity is defined as 
changes of mitochondrial activity, content or oxidative phosphorylation capacity due to 
altered metabolic conditions (Hoppeler and Fluck 2003; Pagel-Langenickel, Schwartz et al. 
2007)  induced by cellular aging or by several diseases like diabetes mellitus and cancer. 
Among the several methodological approaches used to study mitochondrial plasticity, mass 
spectrometry-based proteomics presents the added dimension of allowing the large-scale 
characterization of mitochondrial protein profile. The comparative analysis of 
mitochondrial proteome in distinct conditions might contribute to the understanding of the 
relationship between mitochondrial dysfunction and diseases. The proteomics-based 
methodological approaches used in the study of mitochondrial plasticity in 
pathophysiological conditions are reviewed in Chapter II. In this section, the main findings 
on mitochondrial plasticity in cardiac and skeletal muscles are examined in diabetes 
mellitus, cancer and aging. 
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2.3.1. Mitochondrial plasticity in Diabetes mellitus  
 
Mitochondria have an essential role in fatty acid and glucose metabolism and thus are 
likely to be impacted by impaired metabolism related to diabetes mellitus (Duncan 2011). 
Several studies on mitochondrial plasticity in cardiac and skeletal muscles further support a 
connection between mitochondrial dysfunction and both type 1 diabetes mellitus (T1DM) 
(Dabkowski, Williamson et al. 2009; Ferreira, Guerra et al. 2013) and type 2 diabetes 
mellitus (T2DM) (Ritov, Menshikova et al. 2005; Dabkowski, Baseler et al. 2010) and 
related complications, as cardiomyopathy. Indeed, cardiomyopathy is a common 
complication among diabetics, leading to increased heart failure and ultimately to death 
(Sander and Giles 2003; Shen, Zheng et al. 2004; Duncan 2011; Maisch, Alter et al. 2011). 
The mechanisms responsible for this pathological condition are complex and continue to 
be elucidated (Boudina and Abel 2010; Maisch, Alter et al. 2011). Altered energy 
metabolism towards increased rate of fatty acid oxidation, enlarged ROS production, 
impaired mitochondrial calcium handling and altered lipid content are among the 
mechanisms that may contribute to mitochondrial dysfunction in the diabetic heart 
(Duncan 2011). Skeletal muscle is the most insulin-sensitive tissue and is the source for 
more than 80% of insulin-stimulated glucose uptake in humans (Patti and Corvera 2010), 
being the predominant site of insulin-resistance in T2DM (Mogensen, Sahlin et al. 2007). 
Indeed, diabetes mellitus induces diverse structural, metabolic and functional changes in 
skeletal muscle. Briefly, diabetes mellitus diminish the functional capacity of skeletal 
muscle leading to muscle weakness, causes metabolic disturbance characterized by 
reduced cellular glucose uptake and fatty acid oxidation, and structural changes as muscle 
atrophy, augmented lipid deposition as well as muscle fiber changes (Sun, Liu et al. 2008). 
 
Studies with human subjects and animal models provide evidences of altered 
mitochondrial morphology in skeletal muscle and heart mitochondria in response to T2DM 
and T1DM. Electron microscopy of skeletal muscle biopsies from obese subjects with 
T2DM revealed mitochondria of smaller size and number per volume (density) compared 
with those in lean controls (Kelley, He et al. 2002). These findings were supported by 
others (Morino, Petersen et al. 2005) but counteracted by Phielix et al. (2008) that reported 
no differences of mtDNA copy number between T2DM patients, insulin-resistant first-
degree relatives of T2DM patients, and age and body mass index matched controls. Studies 
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with transmission electron microscopy (TEM) also revealed a significantly reduced 
numbers of SS mitochondria in skeletal muscle of T2DM and obese subjects, which was 
associated with reduced electron transport activity per unit mtDNA, suggestive of 
functional impairment (Ritov, Menshikova et al. 2005). Similarly, in heart muscle, SS 
mitochondria from db/db animals presented altered morphology, including a decrease in 
size and internal complexity, whereas IMF showed increased internal complexity 
(Dabkowski, Baseler et al. 2010).  
T1DM was also associated to alterations in mitochondrial content and morphology. 
Skeletal muscle mitochondria of insulin-deficient rats due to administration of 
streptozotocin (STZ) showed loss of cristae and increased electron-dense granules along 
with the accumulation of lipid droplets around mitochondria (Chao, Ianuzzo et al. 1976), 
an increased number of disarrayed cristae and mitochondrial swelling (Chen and Ianuzzo 
1982; Bonnard, Durand et al. 2008). Cardiac muscle cells from STZ-treated rats also 
presented swollen mitochondria, clearing of mitochondrial matrix and incorporation of 
lysosomal membranes into mitochondria matrix (Seager, Singal et al. 1984). Dabkowski, 
Williamson et al. (2009) analyzed mitochondrial populations from heart STZ diabetic rats 
and verified decreases in both size and complexity of IMF, with no significant effect on SS 
mitochondria. In insulin-deficient Akita mice, that develop diabetes as a result of a 
mutation in the insulin gene, unchanged mitochondrial content was reported in heart 
mitochondria when compared to wild-type (WT) mice, despite reduced cristae density and 
greater mean area (Bugger, Boudina et al. 2008). In other studies, an increase in 
mitochondria number was reported in insulin-deficient Akita mice (Bugger, Chen et al. 
2009), in db/db obese diabetic mice and in OVE26 mice (Shen, Zheng et al. 2004). db/db 
mice have a defect in the leptin receptor, leading to obesity and hyperinsulinemia (as 
opposed to the insulin-defective Akita mice) that result in cardiac steatosis. These 
alterations of mitochondrial content were paralleled by changes in the content of 
mitochondrial transcription factor A (Tfam), which was found up-regulated by 4-weeks of 
STZ (Kanazawa, Nishio et al. 2002) and 5-months old OVE26 (Shen, Zheng et al. 2004); 
however, opposite  findings were reported in STZ- heart mitochondria (Ferreira, Guerra et 
al. 2013). Others studies showed that the peroxisome proliferator-activated receptor 
gamma coactivator 1α (PGC-1α), a crucial regulator of mitochondrial metabolism, was 
reduced in skeletal muscle of T2DM patients (Mootha, Lindgren et al. 2003; Patti, Butte et 
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al. 2003) and in heart muscle of type 1 diabetic Akita mice (Bugger, Chen et al. 2009). 
However, in the diabetic heart muscle of insulin-resistant uncoupling protein diphtheria 
toxin A chain (UCP-DTA) (Duncan, Fong et al. 2007) and of leptin receptor–deficient 
db/db mice (Boudina, Sena et al. 2007), mitochondrial biogenesis was accompanied by a 
significant increase in PGC-1α. 
 
The morphological alterations reported in striated muscle mitochondria from diabetic 
subjects are accompanied by impaired mitochondrial functionality, manifested by reduced 
NADH oxidoreductase and citrate synthase activities (Kelley, He et al. 2002). T2DM-
related OXPHOS impairment was paralleled by increased lipid content in myocytes, as 
well as by a relative decrease in the proportion of enzymes regulating oxidative as opposed 
to glycolytic metabolism (He, Watkins et al. 2001; Ritov, Menshikova et al. 2005). The 
comparative analysis of mitochondria subpopulations showed that SS mitochondria but not 
IMF mitochondria displayed reduced ETC activity in T2DM (Ritov, Menshikova et al. 
2005). Dabkowski, Baseler et al. (2010) observed a decrease of OXPHOS complexes I, III, 
IV and V activities and mitochondrial membrane potential, and increased oxidative 
damage exclusively in SSM of db/db mice. Furthermore, inner mitochondrial membrane 
proteins, including those from electron transport chain, ATP synthesis, and mitochondrial 
protein import machinery, were predominantly decreased. Despite being consistent the 
impaired mitochondrial function per unit muscle tissue, controversy exists regarding 
whether mitochondria per se are defective or whether the problem is restricted to 
mitochondrial number. Mogensen, Sahlin et al. (2007) reported a small but significant 
reduction in mitochondrial respiration rate per mitochondrion in skeletal muscle from 
T2DM patients. Moreover, reduced oxygen use under conditions of ADP stimulation 
(coupled respiration) and maximal uncoupling by carbonyl cyanide p-[trifluoromethoxy]-
phenyl-hydrazone were reported in permeabilized skeletal muscle fibers of human patients 
with type 2 diabetes compared with non-diabetic controls (Boushel, Gnaiger et al. 2007). 
However, when data was normalized to mtDNA or to citrate synthase activity no 
differences were noticed, suggesting that T2DM-related blunted mitochondrial respiration 
in muscle is due to a lower mitochondrial content rather than to an intrinsic organelle 
defect (Boushel, Gnaiger et al. 2007). These results were recently supported by other 
studies (Rabol, Larsen et al. 2010; Larsen, Stride et al. 2011).  
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Regarding T1DM, in heart mitochondria isolated from STZ rats (Pierce and Dhalla 1985) 
and from type 1 diabetic Akita mice (Bugger, Chen et al. 2009) a depressed state 3 
respiration and lower ATP synthesis were showed. Mitochondrial calcium uptake was also 
decreased in hyperglycemic rats, being the change fully reverted by 2 weeks of insulin 
administration. Mitochondrial calcium uptake was also reduced in mitochondria from 
diabetic hyperglycemic hearts (Tanaka, Konno et al. 1992; Flarsheim, Grupp et al. 1996). 
Heart mitochondria from STZ-treated diabetic rats not only presented decreased 
mitochondrial respiration but also increased induction of the calcium-mediated 
mitochondrial permeability transition (MPTP) (Oliveira, Seica et al. 2003). Goto-Kakizaki 
rats seem less susceptible to the induction of MPTP, showing larger calcium accumulation 
before the overall loss of mitochondrial impermeability (Oliveira, Rolo et al. 2001). The 
effect of hyperglycemia in STZ heart mitochondrial populations was also studied and 
decreased electron transport chain complex II respiratory activity in diabetic SS and IMF 
was observed, with the decrease being greater in IMF. Furthermore, complexes I and III 
activities were decreased in IMF but were unchanged in SS mitochondria from diabetics 
(Dabkowski, Williamson et al. 2009). The majority of hyperglycemia-induced cardiac 
mitochondrial alterations occur in IMF, which is critical for the process of energy 
generation for muscle contractility (Dabkowski, Williamson et al. 2009; Lumini-Oliveira, 
Magalhaes et al. 2011). In skeletal muscle the maximal rate of oxidative ATP synthesis 
was reduced in male patients with T1DM compared to non-diabetes subjects, suggesting 
that reduced muscle mitochondrial capacity in conjunction with increased glycolytic flux 
represents a significant metabolic shift in T1DM (Crowther, Milstein et al. 2003). 
 
Studies have suggested that the decreased respiratory capacity of mitochondria in diabetic 
striated muscles is due to increased mitochondrial ROS production or alteration in 
antioxidant defense systems or both  (Maxwell, Thomason et al. 1997; Rosen, Nawroth et 
al. 2001; Scheede-Bergdahl, Penkowa et al. 2005; Phielix, Schrauwen-Hinderling et al. 
2008). Mitochondrial ROS activate multiple pathways that lead to cellular damage in the 
setting of hyperglycemia. Several studies reported an association between increased ROS 
production and the progression of diabetic complications in various tissues including heart 
and skeletal muscle (Marra, Cotroneo et al. 2002; Russell, Gastaldi et al. 2003). Tyrosine 
nitration of mitochondrial proteins is a common mechanism by which oxidative  stress 
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causes dysfunctional mitochondria, with particular relevance in  diabetic heart. A 
proteomic approach carried out by Turko, Li et al. (2003) revealed tyrosine nitration of 
several cardiac proteins in rats with alloxan-induced T1DM, including proteins involved in 
energy metabolism (succinyl- CoA:3-oxoacid CoA transferase, creatine kinase). More 
recently, Ferreira, Guerra et al. (2013) reported an increase of STZ-related mitochondrial 
protein nitration, being OXPHOS subunits and metabolic proteins from the Krebs cycle 
and fatty acid oxidation particularly susceptible to this protein modification. The 
accumulation of carbonylated mitochondrial  proteins has also been associated to impaired 
respiratory chain activity in diabetes mellitus (Bonnard, Durand et al. 2008; Ferreira, 
Guerra et al. 2013), playing a crucial role in the pathogenesis of diabetes-related 
cardiomyopathy. Moreover, increased mitochondrial 4-hydroxy-2-nonenal (4-HNE) 
accumulation has been related to the impairment of OXPHOS complex II activity in STZ-
induced T1DM (Lashin, Szweda et al. 2006). Nevertheless, the overexpression of catalase 
or MnSOD seems to restore the T1DM-induced impaired mitochondrial morphology and 
normalize cardiomyocyte contractility (Ye, Metreveli et al. 2004; Shen, Zheng et al. 2006).  
 
2.3.2. Mitochondrial plasticity in Aging 
 
Aging is a complex biological process, characterized by general time-dependent declines in 
the physiological and biochemical functions of many tissues (Harman 1981; Kirkwood 
2005), with marked effect on heart and skeletal muscle function. Mitochondria are severely 
affected by aging, being proposed that the dysfunction of this organelle in particular plays 
a key role in age-related muscle function decline (Trifunovic and Larsson 2008). The role 
of mitochondria in the process of age-dependent deterioration of heart and skeletal muscle 
has become the focus of many studies with the gradually accepted idea that mitochondria 
dysfunction is a major contributor to aging (Cadenas and Davies 2000; Kwong and Sohal 
2000; Short, Bigelow et al. 2005; Figueiredo, Ferreira et al. 2008; Figueiredo, Powers et al. 
2009) and that age-related oxidative damage to mitochondrial DNA, lipids and proteins is a 
key mechanism underlying loss of function (Sohal 2002; Short, Bigelow et al. 2005). 
Several changes can be observed during aging, including a reduced capacity to use oxygen 
along with impaired cardio-circulatory capacity, and degeneration in muscle mass 
characterized by a reduction in muscle fiber diameters and by qualitative and quantitative 
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alterations in muscle fibers (D'Antona, Pellegrino et al. 2003; Doria, Buonocore et al. 
2012).  
Skeletal muscle is one of the most adversely affected tissues with increasing age (Booth, 
Weeden et al. 1994; Carmeli, Coleman et al. 2002) and its functionality has been reported 
to decline 3-10% per decade after the age of 25 (Rogers, Hagberg et al. 1990; Short, 
Bigelow et al. 2005). The hallmarks of aging are a decrease in both skeletal muscle fiber 
number and fiber cross sectional area, known as sarcopenia (Thompson 2009; Calvani, 
Joseph et al. 2013). This age-related skeletal muscle weakness leads to a substantially 
impaired mobility, locomotion, and quality of life (Morley, Abbatecola et al. 2011). 
Cardiac aging is a complex process which includes deposition of extracellular matrix, a 
decrease in cardiomyocites number and an increase in cardiomyocytes size. This age-
related changes leads to cardiac functional decline and is associated with diminished ability 
to meet increased demand (Fares and Howlett 2010; Papp, Czuriga et al. 2012).  
 
The content, morphology, and functional properties of mitochondria decay in striated 
muscle during aging (Shigenaga, Hagen et al. 1994; Huang and Hood 2009; Lanza and 
Sreekumaran Nair 2010; Terman, Kurz et al. 2010; Cheng, Ito et al. 2013). Several studies 
in old human subjects and animal models showed evidences of age-related changes in 
mitochondrial phenotype of striated muscles. TEM analyses revealed that the 
mitochondrial volume density within skeletal muscle changes with age (Conley, Jubrias et 
al. 2000; Corsetti, Pasini et al. 2008). In aged subjects, it is widely accepted that a 
significant proportion of the skeletal muscle mitochondria are abnormally enlarged, 
disrupted and more rounded in shape (Shigenaga, Hagen et al. 1994; Tonkonogi, 
Fernstrom et al. 2003; Terman, Kurz et al. 2010). Similarly, TEM of cardiac mitochondria 
from aged and newborn rats revealed that mitochondria were elongated in newborn mice, 
and gradually became rounded in older mice (Cheng, Ito et al. 2013). Vacuolization of the 
matrix and shortened mitochondrial cristae (Beregi, Regius et al. 1988; Shigenaga, Hagen 
et al. 1994) and giant mitochondria were reported in aged skeletal muscle mitochondria 
(Beregi, Regius et al. 1988) and in mitochondria of senescent cardiomyocytes (Coleman, 
Silbermann et al. 1987). Coupled with these morphological alterations, a decline in 
mitochondrial content, as represented by mitochondrial mtDNA copy number or CS 
activity, has also been demonstrated in skeletal muscle (Barazzoni, Short et al. 2000; Short, 
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Bigelow et al. 2005; Lyons, Mathieu-Costello et al. 2006; Menshikova, Ritov et al. 2006; 
Gouspillou, Bourdel-Marchasson et al. 2013) although this idea is not consensual (Picard, 
Ritchie et al. 2010). These findings are expected due, at least partially, to a decreased 
capacity for mitochondrial biogenesis (Reznick, Zong et al. 2007; Koltai, Szabo et al. 
2010; Joseph, Adhihetty et al. 2012; Koltai, Hart et al. 2012). Indeed, regarding skeletal 
muscle, several studies has been reported an age-associated downregulation of PGC-1α 
(Reznick, Zong et al. 2007; Koltai, Szabo et al. 2010; Joseph, Adhihetty et al. 2012; Koltai, 
Hart et al. 2012), as well as its upstream regulators AMPK and SIRT1 (Reznick, Zong et 
al. 2007; Koltai, Szabo et al. 2010; Koltai, Hart et al. 2012), but accompained by an 
opposite trend by nuclear respiratory factors and Tfam (Lezza, Pesce et al. 2001; Koltai, 
Hart et al. 2012). Unlike skeletal muscle, it has been demonstrate that mitochondrial 
biogenesis increases in the aged heart, as indicated by the increase in mtDNA copy number 
concomitant with significant upregulation of the PGC-1α and its downstream effectors, 
Tfam and nuclear respiratory factors. Indeed, it has been suggest that increased 
mitochondrial biogenesis in aged heart represents a compensatory maladaptive response in 
reaction ATP deficiency, which is also stimulated by age-related oxidative damage to 
mitochondria (Dai and Rabinovitch 2009).  
 
Given the central role of mitochondria in energy production it is not surprising that striated 
muscle mitochondrial bioenergetics became compromised with age (Short, Bigelow et al. 
2005), considering the decreased mitochondrial respiratory capacity and ETC enzyme 
activities reported in aged skeletal muscle (Tonkonogi, Fernstrom et al. 2003; Nair 2005; 
Short, Bigelow et al. 2005; Conley, Jubrias et al. 2007). Functional analysis revealed age-
related reduced activities of complex I and/or complex IV in humans (Coggan, Spina et al. 
1992; Cooper, Mann et al. 1992; Boffoli, Scacco et al. 1994; Rooyackers, Adey et al. 1996; 
Short, Vittone et al. 2003; Tonkonogi, Fernstrom et al. 2003; Chabi, Mousson de Camaret 
et al. 2005; Crane, Devries et al. 2010; Joseph, Adhihetty et al. 2012) and in animal models 
(Sugiyama, Takasawa et al. 1993; Desai, Weindruch et al. 1996; Lenaz, Bovina et al. 1997; 
Barazzoni, Short et al. 2000; Kwong and Sohal 2000; Kerner, Turkaly et al. 2001; 
Kumaran, Subathra et al. 2004; Baker, Betik et al. 2006; Mansouri, Muller et al. 2006; 
Choksi, Nuss et al. 2008; Picard, Ritchie et al. 2010). Nevertheless, some contradictory 
data was reported (Pastoris, Boschi et al. 2000; Gianni, Jan et al. 2004; Capel, Rimbert et 
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al. 2005; O'Connell and Ohlendieck 2009; Picard, Ritchie et al. 2010). Complex II activity 
was showed to be unchanged with age in skeletal muscle mitochondria (Sugiyama, 
Takasawa et al. 1993; Pastoris, Boschi et al. 2000; Fattoretti, Vecchiet et al. 2001; Kerner, 
Turkaly et al. 2001; Capel, Buffiere et al. 2004; Chabi, Mousson de Camaret et al. 2005; 
Picard, Ritchie et al. 2010) but some studies reported opposite findings (Coggan, Spina et 
al. 1992; Boffoli, Scacco et al. 1994; Kumaran, Subathra et al. 2004; Choksi, Nuss et al. 
2008; O'Connell and Ohlendieck 2009). Data regarding complex III activity are 
inconsistent, with some studies reporting a decrease of its activity (Kumaran, Subathra et 
al. 2004; Chabi, Mousson de Camaret et al. 2005; Choksi, Nuss et al. 2008), but others 
observed no changes (Sugiyama, Takasawa et al. 1993; Pastoris, Boschi et al. 2000; 
Kerner, Turkaly et al. 2001; Capel, Rimbert et al. 2005). Divergent subjects’ characteristics 
(e.g. different animal models, wide variation in age subjects across studies, sample size) 
and analytical techniques (e.g. isolation mitochondria) might justify the discrepancies 
among studies regarding aging of striated muscle.  
As a result of impaired enzymes and complexes activities, ATP synthesis diminishes 
within aged skeletal muscle (Drew, Phaneuf et al. 2003; Mansouri, Muller et al. 2006), and 
the whole body maximal oxygen consumption (VO2max) declines (Tonkonogi, Fernstrom 
et al. 2003; Capel, Rimbert et al. 2005; Short, Bigelow et al. 2005). The assessment of 
mitochondrial respiration stimulated with a variety of substrates in the presence of ADP 
revealed that state 3 respiration, respiratory control ratio and ADP/O ratio parameters 
decreased in aged skeletal muscle (Kumaran, Panneerselvam et al. 2005). At rest, muscle 
ATP synthesis was reduced in 30-month, compared to 7-month-old mice, and a lower 
ATP/ADP ratio in 30-month-old mice was reported (Marcinek, Schenkman et al. 2005). 
The age-related decrease of mitochondrial state 3 respiration (Faist, Koenig et al. 1998; 
Figueiredo, Ferreira et al. 2008; Figueiredo, Powers et al. 2009), and of state 4 respiration 
(Kerner, Turkaly et al. 2001) was associated to increased levels of uncoupling protein 2 
(UCP-2) (Barazzoni and Nair 2001) and to decreased content of UCP-3 (Kerner, Turkaly et 
al. 2001) or unchanged UCP-3 (Barazzoni and Nair 2001)  in skeletal muscle. These results 
suggest that increased UCP-2 levels potentially increase the uncoupling of mitochondrial 
respiration to limit ATP production in aging skeletal muscle. However, UCP-3 expression 
may reflect mitochondrial substrate utilization and may be influenced by muscle fiber 
composition and metabolic characteristics. Moreover, a decreased state 4 respiration and 
Mitochondrial plasticity in pathophysiological conditions 
30 
UCP-3 content emerge as a likely mechanism of age-related oxidative damage to tissue 
(Lesnefsky and Hoppel 2006). 
Similarly to skeletal muscle, it is generally believed that mitochondrial function in heart 
declines with age; however, controversies remains (Manzelmann and Harmon 1987; 
Takasawa, Hayakawa et al. 1993; Delaval, Perichon et al. 2004; Yan, Ge et al. 2004; 
Cocco, Sgobbo et al. 2005; Judge, Jang et al. 2005; Wagatsuma and Sakuma 2012). Some 
studies have demonstrated a decline in oxygen consumption in aged heart (Delaval, 
Perichon et al. 2004; Yan, Ge et al. 2004), but others have reported no changes 
(Manzelmann and Harmon 1987; Cocco, Sgobbo et al. 2005). Moreover, some authors 
have shown a differential effect of the aging process on the two mitochondrial populations 
within the cardiac muscle (Fannin, Lesnefsky et al. 1999; Lesnefsky, Moghaddas et al. 
2001; Moghaddas, Stoll et al. 2002; Judge, Jang et al. 2005; Das and Muniyappa 2013). 
Fannin, Lesnefsky et al. (1999) found that IMF mitochondria but not SS mitochondria 
from aged rat hearts exhibited less protein yield and oxidative phosphorylation rates, 
compared with those from adult rat heart. These resultas have been confirmed by others 
(Lesnefsky, Gudz et al. 2001; Moghaddas, Stoll et al. 2002; Das and Muniyappa 2013). 
Regarding ETC complexes, complex I activity appears to be the most susceptible to age-
related decline in the heart (Sugiyama, Takasawa et al. 1993; Castelluccio, Baracca et al. 
1994; Lenaz, Bovina et al. 1997; Andreu, Arbos et al. 1998; Petrosillo, Matera et al. 2009; 
Choksi, Nuss et al. 2011; Das and Muniyappa 2013), although some studies reported no 
significant changes (Kwong and Sohal 2000; Miro, Casademont et al. 2000). Moreover, the 
activities of complexes III (Castelluccio, Baracca et al. 1994; Lesnefsky, Gudz et al. 2001; 
Moghaddas, Stoll et al. 2002; Tatarkova, Kuka et al. 2011) and IV (Sugiyama, Takasawa et 
al. 1993; Castelluccio, Baracca et al. 1994; Andreu, Arbos et al. 1998; Fannin, Lesnefsky 
et al. 1999; Kwong and Sohal 2000; Moghaddas, Stoll et al. 2002; Choksi, Nuss et al. 
2011; Tatarkova, Kuka et al. 2011; Cheng, Ito et al. 2013; Das and Muniyappa 2013) have 
been reported to decrease with aging. Contraditory studies have shown that complex II 
activity  appears to be unaffected (Sugiyama, Takasawa et al. 1993; Miro, Casademont et 
al. 2000) or rather enhanced (Castelluccio, Baracca et al. 1994; Kwong and Sohal 2000) or 
even decreased with aging (Tatarkova, Kuka et al. 2011; Das and Muniyappa 2013). All 
these contraditory findings in heart aging mitochondria seem to reflect variability in 
subjects characteristics (e.g. animal model, age of subjects, sample size) and variability in 
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experimental procedures (e.g. mitochondrial isolation, enzyme assay) to asses 
mitochondrial function within cardiac muscle. Gomez, Monette et al. (2009) demonstrated 
that the formation of supercomplexes involving complexes I, III, and IV decrease in rat 
aged heart. The heart age-related reduction of mitochondrial cardiolipin, which is located 
in the inner mitochondrial membrane, seems to be closely associated to the decrease of 
complex III activity (Paradies, Ruggiero et al. 1998; Lesnefsky, Minkler et al. 2009) and is 
related with a diminished complex I activity (Paradies, Petrosillo et al. 2002; Petrosillo, 
Matera et al. 2009). Complex V activity was also reported to decline in aged heart 
(Guerrieri, Capozza et al. 1993; Davies, Poljak et al. 2001; Yarian, Toroser et al. 2006). 
 
Studies have suggested that the decreased mitochondrial bioenergetic capacity of aged 
striated muscles is due to increased mitochondrial ROS production or changes in  
antioxidant defense systems (Yarian, Toroser et al. 2006). One of the best-known markers 
of age-related protein oxidation is the carbonyl group content, which was reported to 
increase in skeletal muscle (Alves, Vitorino et al. 2010) and in heart in an age-dependent 
way (Yarian, Toroser et al. 2006; Choksi, Nuss et al. 2008). Other types of protein 
modifications, such as 3-nitrotyrosine, was also found in subunits of OXPHOS complexes 
(Kanski, Behring et al. 2005). Indeed, the decline of complexes I and V activities in aged 
mouse heart was related with their higher susceptibility to oxidative damage without 
repercurssions in protein expression levels (Choksi, Nuss et al. 2008). A marked age-
dependent increase in the main antioxidant enzymes (SOD, CAT, GPx) has been shown in 
rat soleus muscle (Ji, Dillon et al. 1990). Concerning SOD activity, several studies showed 
an age-dependent reduction of total SOD and MnSOD in rat skeletal muscle (Lammi-
Keefe, Swan et al. 1984), while other studies did not find changes in the activity of total 
SOD, but reported an increase in MnSOD with age (Carrillo, Kanai et al. 1992). In 
humans, an increased age-dependent activity of MnSOD was particularly evident in several 
types of skeletal muscle (Marzani, Felzani et al. 2005; Barreiro, Coronell et al. 2006). 
Contraditory results have been reported for CAT actitity; however, some studies showed 
no changes (Marzani, Felzani et al. 2005)s, while others described a significant increase 
(Barreiro, Coronell et al. 2006) or decrease (Pansarasa, Felzani et al. 2002). 
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2.3.3. Mitochondrial plasticity in Cancer 
  
Studies focused on mitochondria plasticity in striated muscle of individuals with cancer are 
scarce and mainly target cancer cachexia. Although the cellular and molecular mechanisms 
of cachexia are incompletely understood, some studies have suggested mitochondria as the 
place of energy wasting in cancer cachexia (Julienne, Dumas et al. 2012). Most of the data 
on mitochondrial plasticity in cancer cachexia was retrieved from studies with preclinical 
models and mainly targeted skeletal muscle since muscle loss is an important factor 
affecting cancer patients’ survival. Cancer cachexia-related muscle atrophy contributes to 
physical disability, weakness and decreased capacity of wound healing and reduces 
responsiveness to chemotherapy (Julienne, Dumas et al. 2012). Cardiac dysfunction was 
recently suggested as an overlooked morbidity related to cancer that may occur in tandem 
with cachexia (Tian, Nishijima et al. 2010; Tian, Asp et al. 2011). Heart contractile 
dysfunction in mice with C26 tumor-induced cachexia was related to increased fibrosis, 
deranged myocardium structure, and altered gene expression of contractile proteins (Tian, 
Nishijima et al. 2010; Tian, Asp et al. 2011). However, the contribution of mitochondria to 
cancer-induced heart remodeling was never studied.  
In cancer-related skeletal muscle wasting it was recently reported that mitochondria 
presents altered morphology, decreased OXPHOS activity and increased proteolysis and 
biogenesis (White, Baltgalvis et al. 2011; Shum, Mahendradatta et al. 2012; Wang, Pickrell 
et al. 2012; Fermoselle, Garcia-Arumi et al. 2013). The morphological changes are 
characterized by the presence of electron-lucent areas, which correspond to the loss of 
mitochondria cristae and swelling (Shum, Mahendradatta et al. 2012). TEM analysis of 
skeletal muscle mitochondria from tumor-bearing mice revealed the presence of giant 
mitochondria (Tzika, Fontes-Oliveira et al. 2013). The activation of TNF-alpha-induced 
NF-κB was shown to result in the decreased expression of regulator factors involved in 
mitochondrial biogenesis (e.g. PGC-1α, PPARα, and Tfam) and to affect downstream 
oxidative proteins (citrate synthase, and cytochrome c oxidase), disturbing muscle 
oxidative capacity (Remels, Gosker et al. 2010).Wang, Pickrell et al. (2012), using a 
transgenic tumor-bearing mice over-expressing PGC-1α in skeletal muscle, verified that 
the increased mitochondrial biogenesis was not sufficient to alter the levels of pro-
inflammatory cytokines and prevent the mass loss. Moreover, the higher expression of 
PGC-1α in muscle was suggested to lead to the development of larger tumors.  
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Ushmorov, Hack et al. (1999) were the firsts to investigate mitochondrial oxidative 
phosphorylation in skeletal muscle using a mouse model of cancer cachexia (mice bearing 
fibrosarcoma MCA- 105) and showed a 25% reduction in oxygen consumption and a 
reduction in cytochrome c oxidase activity. More recently, Julienne, Dumas et al. (2012) 
confirmed the reduction of complex IV activity in cachectic rats with peritoneal 
carcinogenesis, that was also related to decreased levels of cytochrome c in skeletal 
muscle. A significant reduction in cytochrome-c oxidase complex subunit IV protein 
expression and in cytochrome c protein was reported in the skeletal muscle of ApcMin/+ 
cachectic mice, an animal model of colorectal cancer that develops cachexia (White, 
Baltgalvis et al. 2011). Decrease of ETC complexes I, II, and IV activities and of 
mitochondrial respiratory chain oxygen consumption was also observed in the 
gastrocnemius of cachectic mice-bearing LP07 lung tumor (Fermoselle, Garcia-Arumi et 
al. 2013) 
Similarly to the observed in other pathophysiological conditions, mitochondrial 
dysfunction in wasted muscle seems to be related to increased oxidative stress, manifested 
by  increased levels of malondialdehyde (MDA) (Gomes-Marcondes and Tisdale 2002), 
greater protein susceptibility to carbonylation and nitration,  and increased content of 2-
hydroxy-4-nonenal- (HNE-) and MDA-protein adducts (Barreiro, de la Puente et al. 2005). 
Among mitochondrial proteins, the ones involved in oxidative phosphorylation seem to be 
more prone to oxidative damage in tumor bearing rat skeletal muscle (Marin-Corral, 
Fontes et al. 2010). Indeed, reactive carbonyl groups and MDA adducts of ATP synthase 
were significantly increased in gastrocnemius of tumor bearing rats. Higher levels of HNE- 
and MDA-protein adducts were also reported in tibialis anterior, soleus, and heart of 
cachectic animals (Marin-Corral, Fontes et al. 2010). Moreover, the same authors reveal 
that the levels of MnSOD were significantly greater in heart of tumor bearing rats. 
However, no studies have evaluated markers of oxidative stress in mitochondria isolated 
from striated muscle of cancer cachectic subjects.  
2.3.4. Integrative overview of striated muscle mitochondrial plasticity in 
pathophysiological conditions 
 
Alterations in morphological, biochemical and functional properties of mitochondria in 
striated muscle mitochondria have been reported in several pathophysiologic conditions as 
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aging, diabetes mellitus and, more recently, in cancer. The alterations that ultimately 
impact cellular functions are overviewed in table 1.  
 
Table 1: Summary of striated muscle mitochondrial alterations in response to aging, diabetes 
mellitus and cancer.  
 
Mitochondrial 
plasticity 
Morphologic 
changes 
Number Bioenergetics Biogenesis 
Oxidative 
stress 
Antioxidant 
systems 
Aging 
Skeletal 
muscle 
↓ density 
↓ volume 
Vacuolization of 
matrix 
↓ cristae 
↑/↓ ↑/↓ ↓ ↑ ↑ 
Cardiac 
muscle 
Giant 
Vacuolization of 
matrix 
↓cristae 
↓ ↑/↓ ↑ ↑ ? 
T1DM 
Skeletal 
muscle 
Swelling 
Vacuolization of 
matrix 
↓cristae 
? ↑/↓ ? ↑ ? 
Cardiac 
muscle 
Swelling 
Vacuolization of 
matrix 
↓cristae 
? ↑/↓ ? ↑ ? 
T2DM 
Skeletal 
muscle 
Smaller 
↓Density 
↑/↓ ↑/↓ ↑/↓ ↑ ? 
Cardiac 
muscle 
Smaller 
↓ Density 
? ↑/↓ ? ↑ ↑ 
Cancer 
Skeletal 
muscle 
Giant Swelling 
↓cristae 
? ↑/↓ ↑/↓ ↑ ? 
Cardiac 
muscle 
? ? ? ? ? ? 
T1DM,Type 1 diabetes mellitus; T2DM, Type 2 diabetes mellitus;↑, increase; ↓, decrease; ?, ↑/↓, 
inconsistent results; ?, no information. 
 
Regardless the pathophysiological stimuli that triggers mitochondrial plasticity, there are 
some similarities in the pattern of disease-related mitochondrial changes. Alterations in 
mitochondria morphology have been reported in all the pathophysiological conditions 
analyzed, including vacuolization of the matrix, shortened cristae and enlargement. No 
studies are known that performed morphological characterization of mitochondria from 
cardiac muscle in cancer. It is widely accepted that the number of cardiac muscle 
mitochondria is diminished with age. Except for cardiac muscle, data are not consistent 
over different studies, possibly justified by the different methods used for its assessment, 
namely in sample preparation. Moreover, once mitochondria are isolated and removed 
from the in vivo environment or fixed within tissue preparations, factors such as osmotic 
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forces, tissue turgor, or membrane integrity may be altered and might easily affect 
mitochondrial morphology, mitochondrial size and number.  
Perturbed mitochondrial biogenesis has been suggested to cause reduced mitochondrial 
number as well as reduced capacity for oxidative phosphorylation in several 
pathophysiological conditions. Despite increased cardiac mitochondrial biogenesis, the 
number of mitochondria seems to reduce with aging. Nevertheless, changes in muscle 
mitochondrial biogenesis in pathophysiological conditions remain a controversial issue, as 
mitochondrial functionality. Most studies reported the impairment of mitochondrial 
functionality with age, diabetes mellitus and cancer based on the experimental assessment 
of oxidative phosphorylation activity or oxygen consumption. However, it is unclear which 
specific mitochondrial complexes are impacted by these pathophysiological conditions. 
Some of discrepancies among studies may be explained by differences in mitochondrial 
isolation procedure and/or methodologies used for measurement of mitochondrial energy 
production (Picard, Ritchie et al. 2010).  
Mitochondrial impairment in striated muscle from aged subjects, with diabetes or with 
cancer seems related to increased oxidative stress, manifested by enlarged levels of 
oxidized mitochondrial proteins. Among mitochondrial proteins more susceptible to 
oxidative damage in such conditions are subunits of OXPHOS complexes and metabolic 
proteins. Concerning antioxidant systems, the overexpression of MnSOD have been 
reported in aged skeletal muscle mitochondria in cardiac mitochondria of T2DM subjects. 
This overexpression might reflect an attempt to restore mitochondria functionality, 
impacted by these conditions. No studies are known that measured the antioxidant capacity 
of mitochondria isolated from striated muscle in cancer and T1DM. 
 
Regarding the multiple pathways underlying mitochondrial impairment in striated muscle, 
pharmacological and non-pharmacological therapeutic strategies targeting these molecular 
processes might be envisioning(Judge and Leeuwenburgh 2007; Toledo, Menshikova et al. 
2008; Rabol, Svendsen et al. 2009; Meex, Schrauwen-Hinderling et al. 2010). Among non-
pharmacological strategies, exercise has been proposed to either prevent or counteract 
striated muscle mitochondrial damage. The benefits of exercise in promoting health are 
well documented (Lee, Shiroma et al. 2012). Adaptations to physical activity include 
increased mitochondrial biogenesis and function, and improvement in antioxidant network, 
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leading to a more effective control of RONS production (Ji, Wu et al. 1991; Judge, Jang et 
al. 2005; Rabol, Svendsen et al. 2009; Alves, Vitorino et al. 2010; Meex, Schrauwen-
Hinderling et al. 2010; Phielix, Meex et al. 2010). 
Despite the considerable efforts made in the study of mitochondrial plasticity in the 
pathophysiological conditions here reviewed, many unanswered questions remains. First, it 
is unclear which specific molecular mechanisms are responsible for mitochondrial 
plasticity in response to aging, diabetes mellitus and cancer. Second, it is unknown whether 
SS and IMF mitochondria are equal contributors to the mitochondrial dysfunction in these 
pathophysiologies. 
 
2.4. The contribution of mitochondria signaling to striated muscle wasting 
 
Muscle dysfunction represents a clinical feature of muscle wasting and is defined as the 
presence of low muscle mass and low muscle function (strength or performance), which 
might occur as a consequence of aging, and it may also result from prolonged periods of 
rest or as a consequence of a sedentary lifestyle (Sakuma and Yamaguchi 2012). 
Moreover, muscle dysfunction accompanies many chronic disease such as chronic heart 
failure, chronic kidney disease, cancer, human immunodeficiency virus (HIV), sepsis, 
immune disorders, and dystrophies (Thomas 2007; Fanzani, Conraads et al. 2012; Gea, 
Casadevall et al. 2012). When muscle wasting is related to chronic diseases is usually 
referred as cachexia and when is consequence of normal aging the term sarcopenia is used 
(Sakuma and Yamaguchi 2012). 
Both, cardiac and skeletal muscles have limited proliferative capacity, thus the regulation 
of their size is mostly based on protein turnover (Bergmann, Bhardwaj et al. 2009). Protein 
synthesis and degradation are tightly coupled biological processes, which balance impacts 
muscle contraction. An altered protein turnover, secondary to the catabolic/anabolic 
imbalance due to decreased protein synthesis or increased protein degradation, results in 
the loss of muscle mass. The two processes are tightly regulated and interrelated (Sandri 
2008; Schiaffino, Dyar et al. 2013). Muscle wasting occurs when protein degradation rates 
exceed protein synthesis, and may be induced in striated muscle by a variety of conditions, 
including starvation, denervation, cancer cachexia, heart failure and aging. Figure 4 
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presents an overview of the main signaling pathways suggested to underlie muscle 
wasting. 
In cardiac and skeletal muscles, two major signaling pathways control protein synthesis, 
the IGF1–Akt–mTOR pathway, acting as a positive regulator, and the myostatin–Smad2/3 
pathway, acting as a negative regulator (Rommel, Bodine et al. 2001; Sandri, Sandri et al. 
2004; Stitt, Drujan et al. 2004; Fanzani, Conraads et al. 2012). In normal conditions, both 
IGF-1 and insulin activate phosphatidylinositol-3 kinase (PI3K) which in turn activates 
Akt [also known as protein kinase B (PKB)]. Activated Akt stimulates mammalian target 
of rapamycin (mTOR) to facilitate protein synthesis (Bodine, Stitt et al. 2001) through the 
phosphorylation and activation of p70S6 kinase, and phosphorylation of eukaryotic 
translation initiator factor 4E binding protein 1 (4E-BP1), which reliefs the repression of 
the protein initiation factor eukaryotic translation initiator factor 4E (eIF-4E) (Glass 2003). 
In addition, activated Akt phosphorylates the transcription factor Forkhead box O (FoxO) 
sequestering FoxO to the cytoplasm, preventing the transcription of key genes involved in 
protein degradation, such as the E-3 ligases Muscle Ring Finger 1 (MuRF-1) and atrogin-1 
(also called Muscle Atrophy F-box (MAFbx)) in proteasome mediated proteolysis (Sandri, 
Sandri et al. 2004) and Bnip3 in lysosome mediated proteolysis (Zhao, Brault et al. 2007). 
Muscle wasting due to reduced Akt signaling was observed in different pathophysiological 
conditions (Price, Bailey et al. 1996; Penna, Bonetto et al. 2010; Toth, Ward et al. 2011).  
A negative regulator of muscle bulk is myostatin, also known as member of transforming 
growth factor-beta (TGF-β) family, which is expressed predominantly in skeletal muscle 
(Springer, Adams et al. 2010; Elkina, von Haehling et al. 2011). Upon binding to its type II 
activin receptor (ACTRII), it phosphorylates and activates transcription factors Smad2/3, 
inhibiting Akt activity (Amirouche, Durieux et al. 2009; Trendelenburg, Meyer et al. 2009; 
Argiles, Orpi et al. 2012). Interruption of myostatin’s gene expression leads to muscle 
hypertrophy and hyperplasia (McPherron et al., 1997). Another pathway playing a 
consistent role in muscle wasting relies on the activity of the transcription factor nuclear 
factor-kappaB (NF-κB) (Kandarian and Jackman 2006), which is activated by several pro-
inflammatory cytokines (e.g. TNF-α, IL-6) as well as tumor-derived factor proteolysis-
inducing factor (PIF). Activated NF-κB translocates into the nucleus and initiates the 
transcription of E3 ligases as well as other subunits involved in proteasome mediated 
proteolysis, such as ubiquitin and proteasome subunits (Tisdale 2009). 
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Figure 4: Overview of the molecular pathways involved in muscle wasting, which can be 
viewed as the result of protein synthesis/degradation imbalance. 
Protein synthesis and degradation are regulated by several multiple signaling pathways, 
many of which converge at common intermediates and/or crosstalk with one another. 
Dotted lines depict pathways whose molecular mechanisms and role in muscle have yet to 
be completely defined. GR, glucocorticoid receptor; ER, endoplasmic reticulum (adapted 
from Bonaldo and Sandri 2013). 
 
 
Another pathway that promotes enhanced proteolysis in striated muscle is the AMP kinase 
(AMPK)-FoxO3 axis (Romanello, Guadagnin et al. 2010; Romanello and Sandri 2010). 
Specifically, AMPK is a cellular sensor of energy levels, and active AMPK modulates 
FoxO3 action independently of Akt (Greer, Oskoui et al. 2007; Romanello, Guadagnin et 
al. 2010). Increased cellular levels of active AMPK results in the activation of the 
transcriptional activating factor FoxO3, resulting in increased expression of atrogin-1, 
MuRF-1, LC3, and Bnip3 that play role in in the degradation of contractile proteins via the 
ubiquitin-proteasome system and autophagy (Greer, Oskoui et al. 2007; Romanello, 
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Guadagnin et al. 2010). Therefore, AMPK activation of FoxO3 can accelerate muscle 
protein breakdown via both the ubiquitin- proteasome system and autophagy. 
The degradation of striated muscle proteins is controlled by three major proteolytic 
systems, the lysosomal protease system, the calcium-activated system (calpains) and ATP-
dependent ubiquitin-proteasome system. These systems work together to degrade muscle 
proteins and involve a variety of atrophy related genes or atrogenes, which are controlled 
by specific transcription factors, such as FoxO3 (Tisdale 2005; Powers, Kavazis et al. 
2007; Fanzani, Conraads et al. 2012; Bonaldo and Sandri 2013). Lysosomal cathepsins are 
mainly responsible for degrading extracellular proteins and cell receptors. Calcium 
activated system calpains are involved in myofibrillar disassembly, releasing myofibrils for 
the ubiquitin-proteasome system, which plays a predominant role in the degradation of 
myofibrillar proteins. Ubiquitin might be covalently attached to a lysine residue of the 
target protein under the sequential function of a series of enzymes: ubiquitin activating 
enzyme (E1), the ubiquitin carrier protein (E2), and ubiquitin protein ligase (E3) (Pickart 
2001). Two E3 ligases, atrogin-1 (or MAFbx) and MuRF-1 are highly induced during 
skeletal muscle wasting (Bodine, Stitt et al. 2001; Gomes, Lecker et al. 2001). Attachment 
of multiple ubiquitin molecules (called polyubiquitination) is a tag in the protein for its 
recognition and degradation by the 26S proteasome (Baumeister, Walz et al. 1998). The 
26S proteasome has three types of proteolytic activity: chymotrypsin-like, trypsin-like and 
caspase-like activities, and the combination converts protein into peptides with six to nine 
amino acids. The peptides are further degraded to amino acids by other enzymes, such as 
tripeptidyl peptidase II (TPPII). Other findings also suggest a role of autophagy-lysosome 
system, where damaged organelles and proteins are degraded in skeletal muscle (Vicencio, 
Galluzzi et al. 2008). The overexpression of the autophagy marker Bnip3 per se could 
stimulate autophagy in the skeletal muscle, and similar to E3-ligases, Bnip3 expression is 
regulated by FoxO in skeletal muscle wasting (Mammucari, Schiaffino et al. 2008). 
 
The involvement of mitochondria in muscle wasting seems a common feature (Adhihetty, 
Ljubicic et al. 2005; Marzetti, Hwang et al. 2010; Romanello, Guadagnin et al. 2010; 
Romanello and Sandri 2010; Powers, Smuder et al. 2011; Singh and Hood 2011; White, 
Baynes et al. 2011). The loss of mitochondria in wasted muscles, changes in organelle 
morphology, increased mitochondrial ROS production, and impaired ATP production 
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might produce signals that contribute to muscle wasting (Powers, Wiggs et al. 2012). The 
increased mitochondrial ROS production seems to promote muscle wasting by enhancing 
proteolysis and depressing protein synthesis. Indeed, increased ROS levels have been 
shown to activate both calpains and caspase-3, and increase the expression of key E3 
ligases, leading to increased muscle protein degradation by the ubiquitin-proteasome 
system (Li, Chen et al. 2003; McClung, Whidden et al. 2008; Powers and Jackson 2008; 
Powers, Smuder et al. 2011). Exposure of cardiac myocytes to H2O2 can depress protein 
synthesis by 49% (Pham, Sugden et al. 2000), being predicted to occur at the level of 
mRNA translation, due, in part, to a decrease in Akt/mTOR signaling (Powers, Smuder et 
al. 2011). 
Several factors, including increased mitochondrial ROS production, can promote the 
permeabilization of the OM and the consequent release of pro-apoptotic factors such as 
apoptosis-inducing factor (AIF) and cytochrome c (Adhihetty, Ljubicic et al. 2005; Tait 
and Green 2010). In cytoplasm, cytochrome c can activate caspase-3 and lead to muscle 
protein breakdown. In skeletal muscle, the activation of apoptosis leads to decreased 
myonuclear number, which was reported in inactivity, in chronic heart failure and aging 
(Allen, Linderman et al. 1997; Adams, Jiang et al. 1999; Leeuwenburgh, Gurley et al. 
2005; Siu, Pistilli et al. 2005). The reduction in the number of nuclei in muscle fibers 
would decrease its transcriptional capacity and therefore reduce the overall protein 
synthesis (Powers, Wiggs et al. 2012). Experiments with caspase-3 knockout animals 
suggest that the absence of caspase-3 protects against denervation-induced muscle wasting 
by suppressing apoptosis and protecting against the loss of myonuclei (Plant, Bain et al. 
2009). Accumulating evidence suggests that enhanced activation of apoptosis takes place 
in aged skeletal muscle, likely contributing to the development of sarcopenia (Marzetti and 
Leeuwenburgh 2006). In this scenario, mitochondrial apoptotic signaling might be seen as 
a central mechanism underlying the pathogenesis of age-related muscle atrophy 
(Adhihetty, O'Leary et al. 2008). Other findings suggest that inactivity-induced 
mitochondrial energy stress can promote enhanced proteolysis via the AMP kinase 
(AMPK)-FoxO3 axis (Romanello, Guadagnin et al. 2010; Romanello and Sandri 2010). 
Despite being recognized as a major factor contributing to muscle wasting, the signaling 
mechanisms that lead to mitochondrial dysfunction are just starting to be disclosed. 
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3. Aims of the study 
 
Regarding the role of mitochondria in striated muscle adaptation to aging, diabetes mellitus 
and cancer, the general goal of the present thesis was to characterize the mitochondrial 
plasticity in skeletal and cardiac muscles in these pathophysiological conditions. To 
accomplish this, specific purposes were outlined in the different original research articles 
(Papers I - IV) that comprise chapter IV:  
 
i) Identify the main mitochondrial protein targets to oxidation and nitration in 
heart of young, old active and old sedentary mice, and relate it with 
mitochondrial respiratory chain activity (Paper I). 
 
ii) Evaluate the influence of cellular location of mitochondria in respiratory chain 
activity and OXPHOS subunits’ susceptibility to oxidative and nitrative stress 
in rat cardiac muscle (Paper II). 
 
iii) Determine whether IMF mitochondria protein quality control system is affected 
by STZ-induced hyperglycemia and how they relate to mitochondrial 
dysfunction in rat skeletal muscle (Paper III). 
 
iv) Investigate the interplay between urothelial carcinoma-induced catabolic profile 
and skeletal muscle phenotype focusing on mitochondrial plasticity in 
gastrocnemius muscle. Analyse the potential regulatory role of protein quality 
control system in mitochondria activity and in mitochondrial proteins’ 
susceptibility to oxidation (Paper IV). 
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General discussion 
Mitochondria have considerable plasticity and adapt itself to requirements of the organelle 
and of the cell (Dimmer and Rapaport 2008). These organelles are very dynamic and 
respond rapidly and adequately when challenged by physiological or pathological stimuli 
(Sandri 2008; Romanello and Sandri 2013). Such adaptation is particularly important in 
striated muscle because it has a high metabolic rate. Because of that, heart and skeletal 
muscles have a high content of mitochondria to keep up with ATP production for the 
maintenance of contractile activity (Dorn 2013; Romanello and Sandri 2013). So, changes 
in mitochondria homeostasis would have deleterious consequences on muscle 
functionality, playing mitochondrial plasticity a key role in the regulation of 
cardiac/skeletal muscle cells homeostasis (Romanello and Sandri 2013). 
Diabetes mellitus and cancer are common diseases with tremendous impact on health 
worldwide (Giovannucci, Harlan et al. 2010). Both diabetes mellitus and cancer are 
prevalent diseases whose incidence is increasing globally. Worldwide, cancer is the 2nd 
and diabetes mellitus is the 12th leading cause of death (Lopez, Mathers et al. 2006). 
Moreover, elderly population presents a higher risk for these diseases as well as for 
cardiovascular ones (Jahangir, Sagar et al. 2007). Considering the aging population in 
Europe, increasing demands for health care are predicted. So, the better knowledge of these 
diseases’ pathogenesis and the development of new and more effective therapeutic 
approaches are likely to boost health care conditions, with social and economic impact in 
countries. 
Progressive mitochondrial dysfunction is a common cellular event to the pathogenesis of 
diseases as cancer (Julienne, Dumas et al. 2012; Shum, Mahendradatta et al. 2012) and 
diabetes mellitus (Dabkowski, Williamson et al. 2009; Dabkowski, Baseler et al. 2010; 
Ferreira, Guerra et al. 2013), and also contributes to the aging process (Cadenas and 
Davies 2000; Kwong and Sohal 2000; Short, Bigelow et al. 2005; Figueiredo, Ferreira et 
al. 2008; Figueiredo, Powers et al. 2009; Alves, Vitorino et al. 2010). Changes in 
mitochondria include the appearance of morphological alterations as abnormally rounded 
mitochondria, increased oxidative damage and reduced oxidative capacity. These 
morphological, biochemical and bioenergetics changes might ultimately lead to 
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mitochondrial-mediated apoptosis. Despite numerous studies linking these 
pathophysiologic conditions to mitochondrial dysfunction, progress in the comprehension 
of the molecular mechanism(s) involved has been extremely slow. To bring new insights 
on the molecular pathways underlying mitochondrial dysfunction in pathophysiological 
conditions, we performed a characterization of mitochondrial plasticity in striated muscle 
in response to aging, diabetes mellitus and cancer (Studies I, III and IV). 
In striated muscles there are two populations of mitochondria with specific biochemical, 
morphological and functional features, being IMF the most abundant (80%) when 
compared with SS (20%) mitochondria (Hoppeler 1986). Besides being in higher amount, 
IMF mitochondrion presents increased OXPHOS activity, which seem related to a lower 
susceptibility of mitochondrial proteins to carbonylation in heart. Our data highlighted, for 
the first time, a localization dependence of cardiac OXPHOS activity and susceptibility to 
post-translational modifications, particularly to carbonylation and nitration. Curiously, the 
nitration of OXPHOS subunits does not seem to impact respiratory chain activity 
considering the higher levels observed in IMF mitochondria. However, unlike 
carbonylation, the role of protein nitration in cell physiology is controversial. Some authors 
(Aulak, Koeck et al. 2004; Gow, Farkouh et al. 2004) argue that tyrosine nitration is 
selective, dynamic and reversible, being potentially benefic (Study II).  
Unless mitochondrial isolation targets the separation of both populations through the use of 
density gradients and ultracentrifugation, the biochemical and functional alterations 
reported in literature might be mainly attributed to IMF mitochondria, considering its 
greater abundance. According to several authors (Lesnefsky, Gudz et al. 2001; Williamson, 
Dabkowski et al. 2010; Baseler, Dabkowski et al. 2011; Chomentowski, Coen et al. 2011), 
IMF mitochondria are more susceptible to external stimuli, to diseases as diabetes mellitus, 
and to the aging process. 
A number of evidences link mitochondria function to signaling pathways that regulate 
lifespan and the aging process. Decreased mitochondrial size, diminished expression of 
genes involved in mitochondrial biogenesis, altered mitochondrial activity and oxidative 
stress are some of the alterations reported in aged striated muscle (Barazzoni, Short et al. 
2000; Short, Bigelow et al. 2005; Alves, Vitorino et al. 2010; Koltai, Hart et al. 2012; 
Cheng, Ito et al. 2013). Nevertheless, the causes of age-related mitochondrial impairment 
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are still a matter of controversy. In aged heart, we verified an association between the 
decline in bioenergetic function and the accumulation of oxidatively modified proteins. 
Among the mitochondrial proteins more prone to carbonylation and nitration we identified 
OXPHOS subunits, MnSOD and enzymes from lipid metabolism. The high susceptibility 
of OXPHOS subunits to oxidative damage might justify, at least in part, the lower 
OXPHOS complexes activity observed in aged heart. This age-related mitochondrial 
impairment seems to be modulated by lifestyle, with sedentary behavior worsening the 
functional consequences of aging manifested by an increased content of nitrated 
mitochondrial proteins and lower OXPHOS activity (Study I).   
 
In an animal model of type 1 diabetes mellitus obtained by the administration of STZ we 
observed the impairment of OXPHOS activity in skeletal muscle. STZ has a half-life of six 
hours being readily metabolized, and induces rapid and sustained diabetes. We analyzed 
gastrocnemius muscle after four months of hyperglycemia, a time-point of manifested 
diabetes-related complications (Topping and Targ 1975) and of 30% loss of muscle mass, 
with animals evidencing normal cage activity. Regarding previous findings that suggest 
IMF mitochondria as the mitochondrial population more susceptibility to hyperglycemia 
(Williamson, Dabkowski et al. 2010), our study focused on the potential modulatory role 
of PQC system in IMF functionality. Despite the higher content of mitochondria in 
gastrocnemius muscle of STZ-diabetic rats, given by the significant higher mtDNA-to-
muscle mass ratio, IMF mitochondria presented lower activity of OXPHOS complexes III 
and V. Similarly to the observed in aged mitochondria (Study I) and in cardiac 
mitochondria from diabetics (Ferreira, Guerra et al. 2013), an association between lower 
ATP production ability and increased carbonylated protein levels was noticed, partially 
justified by the impairment of PQC system. Besides decreased levels of Lon and 
paraplegin proteases, a diminished activity of Lon, metalloproteases (PreP, LAP-3 and 
MIP) and cathepsin D was detected by zymography-LC-MS/MS in isolated IMF 
mitochondria. Our data highlighted, for the first time, the association between the down-
regulation of AAA proteases, particularly of the membranar paraplegin and the matrix Lon 
protease, and diabetes-related mitochondrial dysfunction in skeletal muscle (Study III).  
Muscle wasting is observed in many diseases, being related to poor quality of life and 
increased risk of mortality (Sakuma and Yamaguchi 2012). Skeletal muscle wasting is the 
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most prominent feature of cancer cachexia. Actually, increased efforts have been made to 
understand the mechanisms underlying cancer-induced skeletal muscle wasting aiming to 
develop strategies to prevent or counteract the loss of muscle mass. Mitochondria 
dysfunction was previously linked to muscle wasting in peritoneal carcinosis-induced 
cachexia (Julienne, Dumas et al. 2012). Using an animal model of BBN-induced urothelial 
carcinoma characterized by a significant loss of body weight and decreased gastrocnemius 
mass, we studied the relationship between mitochondrial dynamics and muscle wasting. 
The impaired OXPHOS activity observed in the gastrocnemius of BBN rats was paralleled 
by the accumulation of oxidatively modified mitochondrial proteins. Despite the higher 
proteolytic activity observed in zymo gels, lower levels of the AAA protease paraplegin 
and the matrix Lon protease were detected in the gastrocnemius muscle of BBN rats, 
suggestive of mitochondrial PQC system impairment. Lower functionality of 
mitochondrial PQC system seems to be linked to an increased production of ROS, 
contributing to the accumulation of oxidatively modified mitochondrial proteins and 
consequently to muscle dysfunction in cancer subjects. Alterations in mitochondria were 
noticed to occur along with the muscle catabolism induced by the neoplastic growth, 
further supporting mitochondria as a critical regulator of muscle protein turnover. 
 
The integrated analysis of data retrieved from our experimental studies revealed some 
similarities in the pattern of disease-related mitochondrial changes (Figure 1). Regarding 
skeletal muscle (Figure 1A), we studied the impact of type 1 diabetes mellitus and bladder 
cancer on mitochondrial plasticity and data highlighted: i) the impaired capacity of 
mitochondria to cope the cellular demands of ATP; ii) the exacerbation of mitochondrial 
oxidative stress; iii) the increased accumulation of damaged mitochondrial proteins; and 
iv) the down-regulation of mitochondrial PQC system. All these inter-related processes 
contribute to mitochondrial dysfunction and ultimately lead to muscle wasting. In aged 
cardiac muscle we also observed: i) a decreased activity of mitochondrial respiratory chain; 
ii) enhanced mitochondrial oxidative stress; and iii) increased accumulation of oxidative 
damaged mitochondrial proteins (Figure 1B). Similar findings were reported in heart from 
STZ-induced diabetic animals (Ferreira, Guerra et al. 2013).  
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Figure 1: Schematic overview that integrates all data retrieved from the experimental studies. 
Mechanisms of mitochondrial plasticity in skeletal muscle during diabetes mellitus and 
cancer (A) and in cardiac muscle during aging and diabetes mellitus (B). 
OXPHOS, Oxidative phosphorylation system; PQC, Protein quality control. Figure was made 
based on Servier Medical Art. 
B 
A 
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Although the molecular details are far from being clarified, mitochondrial dysfunction in 
striated muscle, manifested by decreased activity respiratory chain complexes, is due to, at 
least partially, an increased production of ROS with consequent accumulation of 
oxidatively modified mitochondrial proteins, not eliminated by the proteases from the 
mitochondrial PQC system. Independently of stimuli, the mitochondrial proteins more 
prone to oxidative damage are OXPHOS subunits, metabolic proteins as aconitate 
hydratase and MnSOD. The accumulation of these oxidized mitochondrial proteins might 
lead to the exacerbation of ROS production and to the decreased ability to produce ATP, 
compromising the homeostasis of striated muscle in aging, diabetes mellitus and cancer. 
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Conclusions 
 
Mitochondrial dysfunction is known to play a critical role in many pathophysiological 
conditions; however, the mechanisms involved are not disclosed. To give new insights on 
this issue, four experimental works were developed targeting striated muscle mitochondrial 
plasticity in aging, type 1 diabetes mellitus and cancer. Data obtained allowed to conclude 
that: 
i) Age-related impairment of cardiac muscle mitochondria was manifested by 
decreased OXPHOS activity, paralleled by an increased susceptibility of 
mitochondrial proteins to oxidation (mainly OXPHOS complexes, MnSOD and 
enzymes from lipid metabolism), which is worsened by sedentary lifestyle; 
 
ii) Among mitochondrial populations in heart, IMF presented higher OXPHOS 
activity then SS mitochondria; OXPHOS subunits were more susceptibility to 
carbonylation in SS and to nitration in IMF mitochondria. Unlike nitration, the 
increased carbonylation of OXPHOS complexes’ subunits seem an underlying 
mechanism of decreased cardiac mitochondria functionality; 
 
iii) Type 1 diabetes mellitus-related impairment of IMF mitochondria in gastrocnemius 
muscle was associated to decreased activity of mitochondrial PQC system 
involving the down-regulation of AAA-proteases, namely paraplegin and Lon, with 
the subsequent accumulation of damaged mitochondrial proteins and decreased 
OXPHOS activity; 
 
iv) In urothelial carcinoma-related gastrocnemius muscle wasting, decreased OXPHOS 
activity was associated to the accumulation of oxidatively modified mitochondrial 
proteins due to, at least in part, the down-regulation of mitochondrial proteases 
from the PQC system. This impaired mitochondrial activity was related to the 
catabolic profile promoted by pro-inflammatory cytokines and myostatin. 
In overall, experimental findings presented in this thesis support the notion that regardless 
the pathophysiological stimuli that unleash mitochondrial plasticity, the ability for ATP 
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production is diminished in striated muscle due to increased oxidative damage of 
biomolecules, being OXPHOS subunits particularly prone. Our data highlighted, for the 
first time, the impact of PQC system impairment in the accumulation of oxidized proteins, 
exacerbating mitochondrial dysfunction in pathophysiological conditions. The association 
between mitochondrial dysfunction due to the accumulation of damaged proteins and 
bladder cancer cachexia was also reported for the first time.  
Future studies focused on the dynamics and functional versatility of mitochondrial PQC 
system will not only contribute to a better comprehension of the molecular mechanisms 
that modulate mitochondria functionality but will also allow to define therapeutic targets to 
prevent or counteract pathophysiologic conditions characterized by mitochondrial 
dysfunction. The potential non-pharmacological therapeutic effect of exercise should also 
be more explored envisioning the protection of mitochondrial functionality in striated 
muscle impacted by pathophysiological conditions.  
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STUDY I – EFFECT OF LIFESTYLE ON AGE-RELATED MITOCHONDRIAL PROTEIN OXIDATION IN MICE CARDIAC MUSCLE 
 
Supplementary Table S1: Proteins identified in bands reactive for anti-DNP (grey lines) and anti-3-NT (white lines) antibodies by SDS-PAGE and Western 
blots analysis in whole heart and in mitochondria. (Y - young mice; A - old active mice; S - old sedentary mice). 
 
Band 
No. 
Experimental 
groups 
detected  
Protein name  UNIPROT Accession no./Entry name     Protein MW 
Protein 
pI 
Peptide 
count 
%   
coverage 
  
Functional  
cluster 
  Y A S         Peptide sequence Modification 
Start 
sequence 
End 
sequence 
dMass 
(ppm) 
Prec 
MW 
Theor MW Conf % Conf 
1 x x x 
Very long-chain specific acyl-CoA dehydrogenase P50544|ACADV_MOUSE     70875,50 8,91 22 42,4     
  ELGAFGLQVPSELGGLGLSNTQYAR Glu->pyro-Glu@N-term 
139 163 
-6 2558,33 2558,31 99 2 
Metabolism 
  NPFGNVGLLMGEAGK Oxidation(M)@10 
494 508 
0 1518,75 1518,75 99 2 
  ENMASLQSSPQHQELFR Oxidation(M)@3 
617 633 
0 2016,93 2016,93 99 1 
  SFAVGMFK Oxidation(M)@6 
73 80 
-8 901,44 901,44 99 2 
  VASGQALAAFCLTEPSSGSDVASIR Trioxidation(C)@11; Thr->Glu@13 
206 230 
-5 2512,19 2512,18 99 1 
ATP synthase subunit alpha, mitochondrial  Q03265|ATPA_MOUSE      
9,22 19 43,9   
OXPHOS   QGQYSPMAIEEQVAVIYAGVR Gln->pyro-Glu@N-term; Oxidation(M)@7 473 493 1 2307,12 2307,12 99 2 
  EAYPGDVFYLHSR Glu->pyro-Glu@N-term 
335 347 
0 1534,72 1534,72 99 2 
Trifunctional enzyme subunit alpha, mitochondrial Q8BMS1|ECHA_MOUSE     82669,85 9,24 13 36,3   
Metabolism 
  SPKPVVAAISGSCLGGGLELAIACQYR Cys->Dha(C)@13; Dioxidation(C)@24 
133 159 
7 2657,37 2657,38 99 2 
Electron transfer flavoprotein-ubiquinone 
oxidoreductase, mitochondrial 
Q921G7|ETFD_MOUSE 
    
68090,93 7,34 11 28,6   
Metabolism   LQINAQNCVHCK Dioxidation(C)@8; Cys->Dha(C)@11 
578 589 
15 1367,64 1367,66 99 1 
  IPVPILPGLPMNNHGNYIVR Oxidation(M)@11 
155 174 
1 2229,21 2229,21 99 1 
Long-chain-fatty-acid--CoA ligase 1  P41216|ACSL1_MOUSE 
    
77923,44 6,81 9 29,8   
Metabolism 
  VKPKPPEPEDLAIICFTSGTTGNPK Propionamide(C)@15 
261 285 
0 2709,40 2709,40 99 2 
Sarcalumenin  Q7TQ48|SRCA_MOUSE     99183,99 4,39 10 15,8   
Signal transduction 
  VYVSSFWPQDYKPDTHR Dioxidation(W)@7 725 741 5 2155,98 2156,00 99 2 
  YQLYTGAEPTTSEFTVLMHGPK Oxidation(M)@18 558 579 -10 2485,21 2485,18 99 1 
  TLMLNEDKPADDYSAVLQR Oxidation(M)@3 478 496 -2 2194,06 2194,06 99 2 
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Dihydrolipoyl dehydrogenase, mitochondrial  O08749|DLDH_MOUSE     54272,35 7,99 8 23,8   
Metabolism 
  VVHVNGFGK Deamidated(N)@5 
147 155 
0 956,51 956,51 99 1 
  ALLNNSHYYHMAHGK Oxidation(M)@11 
90 104 
4 1770,82 1770,83 99 2 
  IPNIYAIGDVVAGPMLAHK Oxidation(M)@15 
347 365 
2 1994,06 1994,07 99 1 
Delta-1-pyrroline-5-carboxylate dehydrogenase, 
mitochondrial  
Q8CHT0|AL4A1_MOUSE 
    
61810,52 8,58 5 16,9   
Metabolism 
  VANEPILAFSQGSPER Ala->Thr@2 
31 46 
0 1743,88 1743,88 99 2 
ADP/ATP translocase 1  P48962|ADT1_MOUSE     32883,1 9,73 4 13,4   
Transport 
  EQGFLSFWR Dioxidation(W)@8 
64 72 
-1 1200,56 1200,56 99 1 
Cytochrome c1, heme protein, mitochondrial  Q9D0M3|CY1_MOUSE     35327,64 9,24 3 39,7   
OXPHOS 
  AANNGALPPDLSYIVR Deamidated(N)@4 
187 202 
-3 1670,87 1670,86 99 1 
Methylmalonate-semialdehyde dehydrogenase 
[acylating], mitochondrial  
Q9EQ20|MMSA_MOUSE 
    
57915,63 8,28 3 16,1   
Metabolism 
  IVNDNPYGNGTAIFTTNGATAR Deamidated(N)@5 
437 458 
-3 2267,09 2267,08 99 2 
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial 
Q8BMF4|ODP2_MOUSE 
    
58778,08 5,70 2 10,8   
Metabolism 
  AAPAAAAAMAPPGPR Oxidation(M)@9 
392 406 
1 1334,68 1334,68 99 2 
Cytochrome b-c1 complex subunit 2, mitochondrial  Q9DB77|QCR2_MOUSE     48234,90 9,26 2 12,6   
OXPHOS 
  LPNGLVIASLENYAPLSR Deamidated(N)@3 
43 60 
24 1927,00 1927,04 99 1 
Calsequestrin-2 OS O09161|CASQ2_MOUSE     48197,24 4,12 3 8,4   
Signal transduction 
  SHPDGYEFLEILK His->Asp@2 
277 289 
3 1524,73 1524,73 99 1 
60 kDa heat shock protein, mitochondrial P63038|CH60_MOUSE     60955,49 5,91 8 23,0   Protein binding/folding 
Cytochrome b-c1 complex subunit 1, mitochondrial  Q9CZ13|QCR1_MOUSE     52768,7 5,75 3 18,8   OXPHOS 
ATP synthase subunit beta, mitochondrial   P56480|ATPB_MOUSE     55262,41 5,24 20 48,4   OXPHOS 
Aconitate hydratase, mitochondrial  Q99KI0|ACON_MOUSE     85463,51 8,08 7 22,8   Metabolism 
Acyl-CoA dehydrogenase family member 9, 
mitochondrial  
Q8JZN5|ACAD9_MOUSE     68707,15 7,96 4 7,4   Metabolism 
Aldehyde dehydrogenase, mitochondrial  P47738|ALDH2_MOUSE     56537,54 7,53 2 11,8   Metabolism 
Amine oxidase [flavin-containing] Q8BW75|AOFB_MOUSE     58412,55 5,82 3 10,2   Metabolism 
Aspartate aminotransferase, mitochondrial P05202|AATM_MOUSE     44579,04 8,97 1 7,9   Metabolism 
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Calcium-binding mitochondrial carrier protein Aralar Q8BH59|CMC1_MOUSE     74569,62 8,43 1 3,8   Transport 
Calreticulin P14211|CALR_MOUSE     47994,52 4,33 1 11,8   Protein binding/folding 
Carnitine O-acetyltransferase P47934|CACP_MOUSE     70839,71 8,63 4 8,9   Metabolism 
Carnitine O-palmitoyltransferase 2, mitochondrial P52825|CPT2_MOUSE     73927,48 8,46 5 16,1   Metabolism 
Catalase 24270|CATA_MOUSE     59765,29 7,72 4 18,0   Redox 
Citrate synthase, mitochondrial  Q9CZU6|CISY_MOUSE     51736,67 8,72 2 8,2   Metabolism 
Creatine kinase S-type, mitochondrial Q6P8J7|KCRS_MOUSE     47473,32 8,64 7 23,6   Signal transduction 
Cytochrome c, somatic  P62897|CYC_MOUSE     11605,44 9,61 4 10,5   OXPHOS 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial  
Q9D2G2|ODO2_MOUSE     48994,52 9,10 2 10,8   Metabolism 
Electron transfer flavoprotein subunit beta  Q9DCW4|ETFB_MOUSE     27623,29 8,25 1 4,7   Metabolism 
Glycerol-3-phosphate dehydrogenase, mitochondrial Q64521|GPDM_MOUSE     80953,74 6,17 1 6,3   Metabolism 
Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial  
Q61425|HCDH_MOUSE     34463,87 8,76 1 3,5   Metabolism 
Isocitrate dehydrogenase [NADP], mitochondrial  P54071|IDHP_MOUSE     50906,18 8,88 1 7,1   Metabolism 
Long-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
P51174|ACADL_MOUSE     47907,95 8,53 1 3,0   Metabolism 
Mitochondrial inner membrane protein  Q8CAQ8|IMMT_MOUSE     83900,08 6,18 3 8,3   Signal transduction 
Myosin-7 Q91Z83|MYH7_MOUSE     222878,85 5,59 1 4,1   Structure 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial  
Q99LC3|NDUAA_MOUSE     40603,43 7,63 1 2,8   OXPHOS 
NADH dehydrogenase [ubiquinone] flavoprotein 1, 
mitochondrial  
Q91YT0|NDUV1_MOUSE     50834,20 8,51 3 24,1   OXPHOS 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 2, mitochondrial 
Q91WD5|NDUS2_MOUSE     52625,66 6,52 4 25,1   OXPHOS 
NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial  
Q91VD9|NDUS1_MOUSE     79748,74 5,51 3 12,1   OXPHOS 
Propionyl-CoA carboxylase beta chain, 
mitochondrial 
Q99MN9|PCCB_MOUSE     58394,00 7,19 1 3,3   Metabolism 
Protein disulfide-isomerase A3  P27773|PDIA3_MOUSE     56678,37 5,88 8 22,4   Redox 
Protein NipSnap homolog 2  O55126|NIPS2_MOUSE     32932,73 9,31 1 8,9   unknown 
Pyruvate kinase isozymes P52480|KPYM_MOUSE     57844,89 7,17 5 17,3   Metabolism 
Serine protease inhibitor A3M  Q03734|SPA3M_MOUSE     47004,04 5,35 1 6,7   Signal transduction 
 182 
Sodium/potassium-transporting ATPase subunit 
beta-1  
P14094|AT1B1_MOUSE     35194,56 8,83 4 16,1   Transport 
Sorting and assembly machinery component 50 
homolog  
Q8BGH2|SAM50_MOUSE     51863,97 6,34 4 16,0   Signal transduction 
Stress-70 protein, mitochondrial  P38647|GRP75_MOUSE     73528,33 5,91 2 8,1   Protein binding/folding 
Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial  
Q8K2B3|DHSA_MOUSE     72585,40 7,06 7 15,7   OXPHOS 
Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, 
mitochondrial  
Q9D0K2|SCOT1_MOUSE     55988,57 8,73 6 22,7   Metabolism 
Tripartite motif-containing protein 72  Q1XH17|TRI72_MOUSE     52816,76 6,01 1 3,6   Transport 
Voltage-dependent anion-selective channel protein 
1  
Q60932|VDAC1_MOUSE     32351,49 8,55 1 3,7   Transport 
Voltage-dependent anion-selective channel protein 
2 
Q60930|VDAC2_MOUSE     31732,84 7,44 1 2,7   Transport 
2 x x x 
ATP synthase subunit beta, mitochondrial P56480|ATPB_MOUSE     55262,41 5,24 25 52,6   
OXPHOS   TIAMDGTEGLVR Oxidation(M)@4 110 121 1 1277,63 1277,63 99 1 
  VALVYGQMNEPPGAR Oxidation(M)@8 265 279 1 1616,80 1616,80 99 1 
Creatine kinase S-type, mitochondrial Q6P8J7|KCRS_MOUSE     47473,32 8,64 24 44,6   
Signal transduction 
  TFLIWINEEDHTR Dioxidation(W)@5 258 270 4 1704,80 1704,81 99 1 
  GWEFMWNER Dioxidation(W)@6 302 310 1 1285,52 1285,52 99 1 
  LGYILTCPSNLGTGLR Propionamide(C)@7 311 326 5 1747,92 1747,93 99 1 
  LGYILTCPSNLGTGLR 
Trioxidation(C)@7; Ser->Asn@9; 
Deamidated(N)@10 
311 326 -6 1752,88 1752,87 99 1 
  TFLIWINEEDHTR Trp->Kynurenin(W)@5 258 270 2 1676,81 1676,82 99 1 
Isocitrate dehydrogenase [NADP], mitochondrial  P54071|IDHP_MOUSE     50906,18 8,88 18 52,4   
Metabolism   LVPGWTKPITIGR Dioxidation(W)@5 160 172 3 1468,84 1468,84 99 1 
  IKVEKPVVEMDGDEMTR Oxidation(M)@10; Oxidation(M)@15 44 60 0 2006,96 2006,97 99 2 
ATP synthase subunit alpha, mitochondrial  Q03265|ATPA_MOUSE     59752,60 9,22 15 43,9   
OXPHOS 
  EAYPGDVFYLHSR Glu->pyro-Glu@N-term 335 347 2 1534,72 1534,72 99 2 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 2, mitochondrial  
Q91WD5|NDUS2_MOUSE     52625,66 6,52 15 49,7   
OXPHOS   AVTNMTLNFGPQHPAAHGVLR Oxidation(M)@5 76 96 0 2246,14 2246,14 99 1 
  IDEVEEMLTNNR Oxidation(M)@7 255 266 0 1477,67 1477,67 99 1 
Cytochrome b-c1 complex subunit 2, mitochondrial Q9DB77|QCR2_MOUSE     48234,90 9,26 20 41,1   OXPHOS 
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  ITSEELHYFVQNHFTSAR Deamidated(N)@12 200 217 0 2179,03 2179,03 99 1 
  LPNGLVIASLENYAPLSR Deamidated(N)@3 43 60 -2 1927,04 1927,04 99 1 
  QVAEQFLNMR Gln->pyro-Glu@N-term 232 241 -8 1217,60 1217,59 99 1 
  SMAASGNLGHTPFLDEL Oxidation(M)@2 437 453 2 1774,82 1774,82 99 1 
  KSMAASGNLGHTPFLDEL Oxidation(M)@3 436 453 0 1902,91 1902,91 99 2 
  NALANPLYCPDYR Propionamide(C)@9 184 196 1 1579,74 1579,75 99 2 
3-ketoacyl-CoA thiolase, mitochondrial  Q8BWT1|THIM_MOUSE     41857,92 8,33 14 44,8   
Metabolism 
  AANEAGYFNEEMAPIEVK Oxidation(M)@12 192 209 3 1997,90 1997,90 99 1 
Trifunctional enzyme subunit beta, mitochondrial  Q99JY0|ECHB_MOUSE     51386,34 9,43 14 32,4   
Metabolism   IPFLLSGTSYKDLMPHDLAR Oxidation(M)@14 63 82 -2 2289,19 2289,18 99 1 
  LNFLSPELPAVAEFSTNETMGHSADR Val->Tyr@11; Dethiomethyl(M)@20 205 230 -5 2848,34 2848,33 99 1 
Cytochrome b-c1 complex subunit 1, mitochondrial  Q9CZ13|QCR1_MOUSE     52768,70 5,75 16 45,2   
OXPHOS   QSVPETQVSILDNGLR Gln->pyro-Glu@N-term 43 58 2 1737,89 1737,89 99 2 
  EVESIGAHLNAYSTR Glu->pyro-Glu@N-term 112 126 2 1627,79 1627,80 99 2 
Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
P45952|ACADM_MOUSE     46481,22 8,60 12 36,6   
Metabolism   ANWYFLLAR Dioxidation(W)@3 198 206 2 1184,60 1184,60 99 1 
  ANWYFLLAR Trp->Kynurenin(W)@3 198 206 -8 1156,61 1156,60 99 1 
Aspartate aminotransferase, mitochondrial P05202|AATM_MOUSE     44579,04 8,97 12 29,3   
Metabolism   ILIRPLYSNPPLNGAR Deamidated(N)@13 310 325 -3 1794,02 1794,02 99 1 
  DAGMQLQGYR Oxidation(M)@4 171 180 -2 1153,52 1153,52 99 1 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial  
Q99LC3|NDUAA_MOUSE     40603,43 7,63 10 29,9   
OXPHOS   LQSWLYASR Dioxidation(W)@4 131 139 1 1154,57 1154,57 99 2 
  QDDWTFHYLR Gln->pyro-Glu@N-term 286 295 -3 1362,60 1362,60 99 2 
Acetyl-CoA acetyltransferase, mitochondrial  Q8QZT1|THIL_MOUSE     44816,12 8,71 7 28,1   
Metabolism 
  EVYMGNVIQGGEGQAPTR Oxidation(M)@4 85 102 1 1920,90 1920,90 99 1 
Fumarate hydratase, mitochondrial  P97807|FUMH_MOUSE     54370,60 9,12 5 13,4   
Metabolism 
  MPIPVIQAFGILK Oxidation(M)@1 85 97 1 1441,83 1441,84 99 2 
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Long-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
P51174|ACADL_MOUSE     47907,95 8,53 6 21,6   
Metabolism 
  SPAHGISLFLVENGMK Oxidation(M)@15 225 240 4 1714,86 1714,87 99 1 
ADP/ATP translocase 1 P48962|ADT1_MOUSE     32904,27 9,73 5 22,8   
Transport   EQGFLSFWR Dioxidation(W)@8 64 72 -3 1200,56 1200,56 99 1 
  GMGGAFVLVLYDEIKK Oxidation(M)@2 281 296 0 1754,93 1754,93 99 1 
Calsequestrin-2  O09161|CASQ2_MOUSE     48197,24 4,12 2 6,5   
Protein binding/folding 
  SHPDGYEFLEILK His->Asp@2 277 289 1 1524,73 1524,73 99 1 
Aconitate hydratase, mitochondrial  Q99KI0|ACON_MOUSE     85463,51 8,08 8 25   Metabolism 
Citrate synthase, mitochondrial Q9CZU6|CISY_MOUSE     51736,67 8,72 9 26,1   Metabolism 
NADH dehydrogenase [ubiquinone] flavoprotein 1, 
mitochondrial  
Q91YT0|NDUV1_MOUSE     50834,20 8,51 7 35,1   OXPHOS 
Actin, alpha cardiac muscle 1  P68033|ACTC_MOUSE     42018,97 5,23 5 29,4   Structure 
Sarcalumenin  Q7TQ48|SRCA_MOUSE     99183,99 4,39 4 12,6   Signal transduction 
Sodium/potassium-transporting ATPase subunit 
beta-1  
P14094|AT1B1_MOUSE     35194,56 8,83 4 18,4   Transport 
Aspartate aminotransferase, cytoplasmic P05201|AATC_MOUSE     46100,39 6,75 5 19,9   Metabolism 
Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
P50544|ACADV_MOUSE     70875,50 8,91 4 8,1   Metabolism 
Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial 
Q8K2B3|DHSA_MOUSE     72585,40 7,06 3 14   OXPHOS 
Alpha-sarcoglycan P82350|SGCA_MOUSE     43286,87 6,00 3 18,1   Structure 
Creatine kinase M-type P07310|KCRM_MOUSE     43044,97 6,58 3 16   Signal transduction 
Tripartite motif-containing protein 72 Q1XH17|TRI72_MOUSE     52816,76 6,01 3 28,3   Transport 
Fructose-bisphosphate aldolase A  P05064|ALDOA_MOUSE     39224,74 8,40 3 14,6   Metabolism 
Succinate dehydrogenase [ubiquinone] iron-sulfur 
subunit, mitochondrial  
Q9CQA3|DHSB_MOUSE     31813,90 8,96 3 23,8   OXPHOS 
Cytochrome c1, heme protein, mitochondrial  Q9D0M3|CY1_MOUSE     35327,64 9,24 3 24   OXPHOS 
Pyruvate dehydrogenase E1 component subunit 
alpha, somatic form, mitochondrial 
P35486|ODPA_MOUSE     43231,63 8,49 2 21,3   Metabolism 
78 kDa glucose-regulated protein  P20029|GRP78_MOUSE     72422,06 5,07 2 11,3   Protein binding/folding 
Stress-70 protein, mitochondrial  P38647|GRP75_MOUSE     73528,33 5,91 2 15,3   Protein binding/folding 
Malate dehydrogenase, mitochondrial  P08249|MDHM_MOUSE     35611,45 8,93 2 30,5   Metabolism 
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Elongation factor Tu, mitochondrial  Q8BFR5|EFTU_MOUSE     49508,35 7,23 3 10,4   
DNA/RNA/Protein 
biosynthesis 
NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial 
Q9D6J6|NDUV2_MOUSE     27285,34 7,00 2 25,4   OXPHOS 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 3, mitochondrial  
Q9DCT2|NDUS3_MOUSE     30149,33 6,67 2 9,1   OXPHOS 
Heat shock cognate 71 kDa protein  P63017|HSP7C_MOUSE     70739,87 5,37 2 13,2   Protein binding/folding 
Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial 
Q9D6R2|IDH3A_MOUSE     39638,71 6,27 2 4,9   Metabolism 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 9, mitochondrial  
Q9DC69|NDUA9_MOUSE     42509,15 9,75 2 8,5   OXPHOS 
Protein NipSnap homolog 2  O55126|NIPS2_MOUSE     32932,73 9,31 2 24,6   unknown 
Acyl-coenzyme A thioesterase 2, mitochondrial Q9QYR9|ACOT2_MOUSE     49652,02 6,91 2 7,9   Metabolism 
Mitochondrial inner membrane protein  Q8CAQ8|IMMT_MOUSE     83900,08 6,18 2 5,7   Signal transduction 
ATP synthase subunit d, mitochondrial  Q9DCX2|ATP5H_MOUSE     18749,45 5,52 1 31,1   OXPHOS 
Sorting and assembly machinery component 50 
homolog  
Q8BGH2|SAM50_MOUSE     51863,97 6,34 2 14,5   Protein binding/folding 
Myosin light chain 3  P09542|MYL3_MOUSE     22421,56 5,03 1 17,2   Structure 
Electron transfer flavoprotein-ubiquinone 
oxidoreductase, mitochondrial  
Q921G7|ETFD_MOUSE     68090,93 7,34 1 5   Metabolism 
Acyl-CoA dehydrogenase family member 10 Q8K370|ACD10_MOUSE     118979,21 8,49 1 6,9   Metabolism 
Short-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
Q07417|ACADS_MOUSE     44946,70 8,96 1 8,7   Metabolism 
Alpha-enolase  P17182|ENOA_MOUSE     47009,63 6,36 1 9,7   Metabolism 
Superoxide dismutase [Mn], mitochondrial  P09671|SODM_MOUSE     24602,93 8,80 1 10,4   Redox 
Voltage-dependent anion-selective channel protein 
1  
Q60932|VDAC1_MOUSE     32351,49 8,55 1 3,7   Transport 
Cytochrome c, somatic  P62897|CYC_MOUSE     11605,44 9,61 1 10,5   OXPHOS 
Electron transfer flavoprotein subunit beta Q9DCW4|ETFB_MOUSE     27623,29 8,25 1 22   Metabolism 
Phosphate carrier protein, mitochondrial  Q8VEM8|MPCP_MOUSE     34843,84 9,11 1 9,5   Transport 
Long-chain-fatty-acid--CoA ligase 1 P41216|ACSL1_MOUSE     77923,44 6,81 1 1,7   Metabolism 
Phosphoglycerate kinase 1  P09411|PGK1_MOUSE     44419,28 8,02 1 5,5   Metabolism 
Cytochrome c oxidase subunit 2  P00405|COX2_MOUSE     25976,40 4,60 1 4,4   OXPHOS 
Protein NDRG2  Q9QYG0|NDRG2_MOUSE     40658,01 5,24 1 9,4   Signal transduction 
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Cathepsin D  P18242|CATD_MOUSE     38007,47 5,63 1 6,6   Proteolysis 
Actin, cytoplasmic 2  P63260|ACTG_MOUSE     41792,84 5,31 5 26,1   Structure 
3 _ x x 
Creatine kinase S-type, mitochondrial Q6P8J7|KCRS_MOUSE     47473,32 8,64 20 56,8   
Signal transduction 
  GWEFMWNER Dioxidation(M)@5 302 310 6 1285,51 1285,519 99 1 
  TFLIWINEEDHTR Dioxidation(W)@5 258 270 5 1704,80 1704,811 99 1 
  TFLIWINEEDHTR Trp->Kynurenin(W)@5 258 270 1 1676,81 1676,816 99 1 
Cytochrome b-c1 complex subunit 2, mitochondrial Q9DB77|QCR2_MOUSE     48234,90 9,26 17 40,4   
OXPHOS 
  ITSEELHYFVQNHFTSAR Deamidated(N)@12 200 217 3 2179,03 2179,03 99 1 
  LPNGLVIASLENYAPLSR Deamidated(N)@3 43 60 4 1927,03 1927,04 99 1 
  NALANPLYCPDYR Dioxidation(C)@9; Carboxy(D)@11 184 196 -7 1584,70 1584,69 99 1 
  SMAASGNLGHTPFLDEL Oxidation(M)@2 437 453 3 1774,81 1774,82 99 1 
  KSMAASGNLGHTPFLDEL Oxidation(M)@3 436 453 2 1902,91 1902,91 99 2 
Cytochrome b-c1 complex subunit 1, mitochondrial  Q9CZ13|QCR1_MOUSE     52768,70 5,75 16 37,7   
OXPHOS 
  NNGAGYFLEHLAFK Deamidated(N)@2 86 99 4 1580,76 1580,76 99 1 
  YETEKNNGAGYFLEHLAFK Deamidated(N)@7 81 99 -7 2231,07 2231,05 99 1 
  QSVPETQVSILDNGLR Gln->pyro-Glu@N-term 43 58 4 1737,88 1737,89 99 1 
  DICSKYFYDQCPAVAGYGPIEQLPDYNR Ser->Ala@4; Dioxidation(C)@11 443 470 -2 3240,46 3240,45 99 1 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10 
Q99LC3|NDUAA_MOUSE     40603,43 7,63 13 45,9   
OXPHOS   LQSWLYASR Dioxidation(W)@4 131 139 5 1154,57 1154,57 99 1 
  QDDWTFHYLR Gln->pyro-Glu@N-term 286 295 4 1362,59 1362,60 99 2 
Aspartate aminotransferase, mitochondrial  P05202|AATM_MOUSE     44579,04 8,97 12 43,5   
Metabolism 
  HFIEQGINVCLCQSYAK Cys->Dha(C)@10; Dioxidation(C)@12 263 279 15 1949,90 1949,93 99 1 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 2, mitochondrial  
Q91WD5|NDUS2_MOUSE     52625,66 6,52 10 37,4   
OXPHOS 
  AVTNMTLNFGPQHPAAHGVLR Oxidation(M)@5 76 96 1 2246,14 2246,14 99 1 
Trifunctional enzyme subunit beta, mitochondrial  Q99JY0|ECHB_MOUSE     51386,34 9,43 11 26,3   
Metabolism 
  LNFLSPELPAVAEFSTNETMGHSADR Oxidation(M)@20 205 230 -5 2848,35 2848,33 99 1 
3-ketoacyl-CoA thiolase, mitochondrial  Q8BWT1|THIM_MOUSE     41857,92 8,33 10 33,3   Metabolism 
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  AANEAGYFNEEMAPIEVK Oxidation(M)@12 192 209 2 1997,90 1997,90 99 1 
  VPPETIDSVIVGNVMQSSSDAAYLAR Oxidation(M)@15 46 71 -12 2734,38 2734,35 99 1 
Fructose-bisphosphate aldolase A P05064|ALDOA_MOUSE     39224,74 8,40 10 29,1   
Metabolism   IGEHTPSALAIMENANVLAR Oxidation(M)@12 154 173 -1 2122,09 2122,08 99 1 
  GVVPLAGTNGETTTQGLDGLSER Thr->Pro@8; Deamidated(N)@9 112 134 -2 2268,13 2268,12 99 1 
Actin, alpha cardiac muscle 1  P68033|ACTC_MOUSE     42018,97 5,23 7 42,4   
Structure 
  QEYDEAGPSIVHR Gln->pyro-Glu@N-term 362 374 9 1482,66 1482,67 99 1 
Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial  
Q9D6R2|IDH3A_MOUSE     39638,71 6,27 7 26,2   
Metabolism   HMGLFDHAAK Oxidation(M)@2 317 326 7 1141,53 1141,53 99 2 
  APIQWEER Dioxidation(W)@5 59 66 8 1059,49 1059,50 99 1 
Malate dehydrogenase, mitochondrial P08249|MDHM_MOUSE     35611,45 8,93 6 38,2   
Metabolism   GYLGPEQLPDCLKGCDVVVIPAGVPR Dehydro(C)@11; Dehydro(C)@15 79 104 1 2692,37 2692,37 99 1 
  FVFSLVDAMNGK Oxidation(M)@9 258 269 3 1342,66 1342,66 99 2 
ADP/ATP translocase 1  P48962|ADT1_MOUSE     32904,27 9,73 9 31,5   
Transport 
  EQGFLSFWR Glu->pyro-Glu@N-term 64 72 8 1150,55 1150,56 99 1 
  GMGGAFVLVLYDEIKK Oxidation(M)@2 281 296 1 1754,93 1754,93 99 2 
  EQGFLSFWR Trp->Kynurenin(W)@8 64 72 -4 1172,57 1172,56 99 1 
Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial 
Q8K2B3|DHSA_MOUSE     72585,4 7,06 5 16,1   
OXPHOS 
  HVNGQDQIVPGLYACGEAACASVHGANR Deamidated(N)@3; Cys->Thr@20 424 451 7 2835,32 2835,34 99 1 
Voltage-dependent anion-selective channel protein 
1  
Q60932|VDAC1_MOUSE     32351,49 8,55 5 37,8   
Transport 
  KLETAVNLAWTAGNSNTR Ala->Cys@9 214 231 -4 1976,98 1976,97 99 1 
Cytochrome c oxidase subunit 2 P00405|COX2_MOUSE     25976,4 4,60 5 23,4   
OXPHOS   MLISSEDVLHSWAVPSLGLK Dioxidation(W)@12 152 171 4 2213,13 2213,14 99 1 
  ILYMMDEINNPVLTVK Oxidation(M)@5 83 98 5 1907,96 1907,97 99 2 
Isocitrate dehydrogenase [NADP], mitochondria P54071|IDHP_MOUSE     50906,18 8,88 13 44   Metabolism 
ATP synthase subunit alpha, mitochondrial  Q03265|ATPA_MOUSE     59752,60 9,22 10 36   OXPHOS 
ATP synthase subunit beta, mitochondrial P56480|ATPB_MOUSE     55262,41 5,24 21 47,1   OXPHOS 
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Aconitate hydratase, mitochondrial  Q99KI0|ACON_MOUSE     85463,51 8,08 9 18,2   Metabolism 
NADH dehydrogenase [ubiquinone] flavoprotein 1, 
mitochondrial  
Q91YT0|NDUV1_MOUSE     50834,20 8,51 6 23,7   OXPHOS 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 9, mitochondrial  
Q9DC69|NDUA9_MOUSE     42509,15 9,75 5 28,4   OXPHOS 
Acetyl-CoA acetyltransferase, mitochondrial Q8QZT1|THIL_MOUSE     44816,12 8,71 6 26,9   Metabolism 
Citrate synthase, mitochondrial  Q9CZU6|CISY_MOUSE     51736,67 8,72 5 14   Metabolism 
Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
P45952|ACADM_MOUSE     46481,22 8,60 6 18,3   Metabolism 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 3, mitochondrial  
Q9DCT2|NDUS3_MOUSE     30149,33 6,67 4 29,7   OXPHOS 
Creatine kinase M-type  P07310|KCRM_MOUSE     43044,97 6,58 4 17,1   Signal transduction 
Myosin light chain 3  P09542|MYL3_MOUSE     22421,56 5,03 3 30,4   Structure 
Succinate dehydrogenase [ubiquinone] iron-sulfur 
subunit, mitochondrial  
Q9CQA3|DHSB_MOUSE     31813,90 8,96 4 28,7   OXPHOS 
Myosin-6 OS=Mus musculus  Q02566|MYH6_MOUSE     223565,34 5,57 3 8,8   Structure 
Aspartate aminotransferase, cytoplasmic  P05201|AATC_MOUSE     46100,39 6,75 4 22   Metabolism 
Long-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
P51174|ACADL_MOUSE     47907,95 8,53 3 16,3   Metabolism 
Succinyl-CoA ligase [GDP-forming] subunit alpha, 
mitochondrial  
Q9WUM5|SUCA_MOUSE     36154,76 9,46 3 12,4   Metabolism 
ATP synthase subunit d, mitochondrial  Q9DCX2|ATP5H_MOUSE     18749,45 5,52 3 24,2   OXPHOS 
Cytochrome c1, heme protein, mitochondrial  Q9D0M3|CY1_MOUSE     35327,64 9,24 4 27,1   OXPHOS 
NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial  
Q9D6J6|NDUV2_MOUSE     27285,34 7,00 3 30,7   OXPHOS 
3-hydroxyisobutyryl-CoA hydrolase, mitochondrial Q8QZS1|HIBCH_MOUSE     39239,12 6,24 2 9,9   Metabolism 
Short-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
Q07417|ACADS_MOUSE     44946,70 8,96 2 12,1   Metabolism 
Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
P50544|ACADV_MOUSE     70875,50 8,91 2 8,7   Metabolism 
Superoxide dismutase [Mn], mitochondrial  P09671|SODM_MOUSE     24602,93 8,80 2 22,5   Redox 
Electron transfer flavoprotein subunit beta Q9DCW4|ETFB_MOUSE     27623,29 8,25 2 12,9   Metabolism 
Calcium-binding mitochondrial carrier protein 
Aralar1  
Q8BH59|CMC1_MOUSE     74569,62 8,43 2 4   Protein binding/folding 
Pyruvate dehydrogenase E1 component subunit 
alpha, somatic form, mitochondrial  
P35486|ODPA_MOUSE     43231,63 8,49 2 15,4   Metabolism 
Protein NipSnap homolog 2  O55126|NIPS2_MOUSE     32932,73 9,31 2 15,7   unknown 
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Cytochrome c oxidase subunit 4 isoform 1, 
mitochondrial  
P19783|COX41_MOUSE     19530,46 9,25 2 19,5   OXPHOS 
Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial  
Q61425|HCDH_MOUSE     34463,87 8,76 2 6,1   Metabolism 
Sarcalumenin  Q7TQ48|SRCA_MOUSE     99183,99 4,39 1 14,3   Signal transduction 
Voltage-dependent anion-selective channel protein 
2 
Q60930|VDAC2_MOUSE     31732,84 7,44 2 15,9   Transport 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 7, mitochondrial  
Q9DC70|NDUS7_MOUSE     24682,87 9,94 1 8   OXPHOS 
Malate dehydrogenase, cytoplasmic P14152|MDHC_MOUSE     36379,97 6,16 1 9   Metabolism 
Mitochondrial inner membrane protein  Q8CAQ8|IMMT_MOUSE     83900,08 6,18 1 3,4   Signal transduction 
Alpha-sarcoglycan P82350|SGCA_MOUSE     43286,87 3,00 1 11,4   Structure 
D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial  
Q80XN0|BDH_MOUSE     38284,97 9,14 1 9,9   Metabolism 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 12 
Q7TMF3|NDUAC_MOUSE     17086,41 9,38 1 8,3   OXPHOS 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 4 
Q62425|NDUA4_MOUSE     9326,79 9,52 1 14,6   OXPHOS 
Cytochrome c, somatic OS=Mus musculus 
GN=Cycs PE=1 SV=2 
P62897|CYC_MOUSE     11605,44 9,61 1 10,5   OXPHOS 
Phosphate carrier protein, mitochondrial  Q8VEM8|MPCP_MOUSE     34843,84 9,11 1 3,9   Transport 
Sodium/potassium-transporting ATPase subunit 
beta-1  
P14094|AT1B1_MOUSE     35194,56 8,83 1 7,2   Transport 
Isocitrate dehydrogenase [NAD] subunit gamma 1, 
mitochondrial  
P70404|IDHG1_MOUSE     42785,44 9,17 1 2,3   Metabolism 
Elongation factor Tu, mitochondrial  Q8BFR5|EFTU_MOUSE     49508,35 7,23 1 9,1   
DNA/RNA/Protein 
biosynthesis 
Protein NDRG2  Q9QYG0|NDRG2_MOUSE     40658,01 5,24 1 8,9   Signal transduction 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 8, mitochondrial  
Q8K3J1|NDUS8_MOUSE     24038,33 5,89 1 16,5   OXPHOS 
Beta-enolase  P21550|ENOB_MOUSE     46893,69 6,81 1 9,9   Metabolism 
Mitochondrial 2-oxoglutarate/malate carrier protein  Q9CR62|M2OM_MOUSE     34023,71 9,95 1 8,6   Metabolism 
NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial 
Q91VD9|NDUS1_MOUSE     79748,74 5,51 1 2,6   OXPHOS 
Pyruvate dehydrogenase E1 component subunit 
beta, mitochondrial 
Q9D051|ODPB_MOUSE     35768,29 5,39 1 12,3   Metabolism 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 10 
Q9DCS9|NDUBA_MOUSE     20892,61 8,36 1 14,2   OXPHOS 
Cytochrome b-c1 complex subunit Rieske, 
mitochondrial  
Q9CR68|UCRI_MOUSE     29367,64 8,92 1 8,8   OXPHOS 
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NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit  
Q9DCJ5|NDUA8_MOUSE     19860,88 8,80 1 7,6   OXPHOS 
Cytochrome c oxidase subunit 6C   Q9CPQ1|COX6C_MOUSE     8337,81 10,13 1 38,2   OXPHOS 
Actin, cytoplasmic 2  P63260|ACTG_MOUSE     41792,84 5,31 4 29,1   Structure 
4 _ x x 
Cytochrome b-c1 complex subunit 1, mitochondrial  Q9CZ13|QCR1_MOUSE     52768,70 5,75 33 58,1   
OXPHOS 
  NNGAGYFLEHLAFK Ammonia-loss(N)@2 86 99 10 1562,74 1562,75 99 2 
  NNGAGYFLEHLAFK Deamidated(N)@2 86 99 4 1580,76 1580,76 99 1 
  IPLAEWESR Dioxidation(W)@6 424 432 12 1131,54 1131,56 99 1 
  RIPLAEWESR Dioxidation(W)@7 423 432 10 1287,64 1287,66 99 2 
  YFYDQCPAVAGYGPIEQLPDYNR Gln->Arg@5; Trioxidation(C)@6 448 470 4 2754,23 2754,24 99 2 
  QSVPETQVSILDNGLR Gln->pyro-Glu@N-term 43 58 6 1737,88 1737,89 99 2 
  EVESIGAHLNAYSTR Glu->pyro-Glu@N-term 112 126 7 1627,78 1627,80 99 2 
  IQEVDAQMLR Oxidation(M)@8 433 442 13 1217,59 1217,61 99 1 
  NALVSHLDGTTPVCEDIGR Oxidation(P)@12; Cys->Tyr@14 397 415 27 2071,96 2072,02 99 2 
  DICSKYFYDQCPAVAGYGPIEQLPDYNR Ser->His@4; Cys->Dha(C)@11 443 470 5 3240,48 3240,50 99 2 
  VASEQSSHATCTVGVWIDAGSR Trioxidation(C)@11; Thr->Glu@12 59 80 -11 2336,06 2336,03 99 2 
  QSVPETQVSILDNGLR Val->Ser@3 43 58 41 1742,81 1742,88 99 1 
ATP synthase subunit beta, mitochondrial  P56480|ATPB_MOUSE     55262,41 5,24 15 49,7   
OXPHOS 
  IMNVIGEPIDER Oxidation(M)@2 144 155 9 1400,68 1400,70 99 1 
  GFQQILAGEYDHLPEQAFYMVGPIEEAVAK Oxidation(M)@20 490 519 -11 3365,67 3365,63 99 2 
  VALVYGQMNEPPGAR Oxidation(M)@8 265 279 8 1616,79 1616,80 99 2 
ATP synthase subunit b, mitochondrial  Q9CQQ7|AT5F1_MOUSE     28948,83 9,11 14 43,4   
OXPHOS 
  KEEEHMIDWVEK Oxidation(M)@6; Dioxidation(W)@9 210 221 11 1619,70 1619,71 99 2 
Cytochrome b-c1 complex subunit Rieske Q9CR68|UCRI_MOUSE     29367,64 8,92 13 51,5   
OXPHOS   AGDFGGYYCPCHGSHYDASGR Cys->Dha(C)@9; Dioxidation(C)@11 228 248 13 2216,83 2216,86 99 2 
  EIDQEAAVEVSQLR Glu->pyro-Glu@N-term; Methyl(I)@2 183 196 -57 1581,89 1581,80 99 2 
Cytochrome c oxidase subunit 2  P00405|COX2_MOUSE     25976,40 4,60 21 44,1   
OXPHOS 
  MLISSEDVLHSWAVPSLGLK Dioxidation(W)@12 152 171 7 2213,13 2213,14 99 1 
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  MLISSEDVLHSWAVPSLGLK Ile->Asn@3 152 171 -9 2182,13 2182,11 99 1 
  MIPTNDLKPGELR Oxidation(M)@1 122 134 8 1498,77 1498,78 99 1 
  MLISSEDVLHSW Oxidation(M)@1; Dioxidation(W)@12 152 163 5 1463,65 1463,66 99 2 
  MLISSEDVLHSWAVPSLGLK Oxidation(M)@1; Dioxidation(W)@12 152 171 2 2229,13 2229,14 99 1 
  ILYMMDEINNPVLTVK Oxidation(M)@4; Oxidation(M)@5 83 98 7 1923,96 1923,97 99 1 
  VVLPMELPIR Oxidation(M)@5 142 151 8 1181,67 1181,68 99 1 
NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial  
Q9D6J6|NDUV2_MOUSE     27285,34 7,00 11 59,7   
OXPHOS   FCCEPAGGLTSLTEPPKGPGFGVQAGL Cys->Dha(C)@2; Dioxidation(C)@3 222 248 -2 2630,27 2630,27 99 2 
  VAEVLQVPPMR Oxidation(M)@10 100 110 10 1253,67 1253,68 99 1 
Mitochondrial 2-oxoglutarate/malate carrier protein Q9CR62|M2OM_MOUSE     34023,71 9,95 11 39,5   
Transport 
  YEGFFSLWK Dioxidation(W)@8 272 280 8 1207,55 1207,55 99 2 
  EEGVPTLWR Dioxidation(W)@8 174 182 10 1117,53 1117,54 99 1 
  ALIGMTAGATGAFVGTPAEVALIR Oxidation(M)@5 123 146 -1 2302,24 2302,24 99 1 
Succinate dehydrogenase [ubiquinone] iron-sulfur 
subunit, mitochondrial  
Q9CQA3|DHSB_MOUSE     31813,90 8,96 13 42,2   
OXPHOS 
  WDPDKTGDKPR Dioxidation(W)@1 49 59 6 1345,62 1345,63 99 1 
  WDPDKTGDKPR FormaldehydeAdduct(W)@1 49 59 10 1325,62 1325,64 99 1 
  QQYLQSIEDR Gln->pyro-Glu@N-term 170 179 6 1261,59 1261,59 99 2 
  MQTYEVDLNK Oxidation(M)@1 60 69 10 1255,56 1255,58 99 1 
  IYPLPHMYVIK Oxidation(M)@7 129 139 7 1388,74 1388,75 99 2 
  WDPDKTGDKPR Oxidation(W)@1 49 59 10 1329,62 1329,63 99 1 
Myosin-6  Q02566|MYH6_MOUSE     223565,34 5,57 9 8,2   
Structure 
  TVTIKEDQVMQQNPPK Oxidation(M)@10 68 83 1 1870,94 1870,95 99 2 
Voltage-dependent anion-selective channel protein  Q60932|VDAC1_MOUSE     32351,49 8,55 9 46,3   
Transport   KLETAVNLAWTAGNSNTR Dioxidation(W)@10 214 231 7 1976,98 1976,99 99 2 
  WNTDNTLGTEITVEDQLAR Thr->Pro@3 88 106 22 2171,00 2171,05 99 2 
ATP synthase subunit d, mitochondrial  Q9DCX2|ATP5H_MOUSE     18749,45 5,52 10 72,7   
OXPHOS 
  LASLSEKPPAIDWAYYR Dioxidation(W)@13 42 58 5 2010,99 2011,01 99 1 
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  SWNETFHAR Dioxidation(W)@2 33 41 10 1178,50 1178,51 99 1 
Creatine kinase S-type, mitochondrial  Q6P8J7|KCRS_MOUSE     47473,32 8,64 8 21,7   
Signal transduction   GIWHNYDK Dioxidation(W)@3 250 257 6 1063,47 1063,47 99 2 
  TFLIWINEEDHTR Dioxidation(W)@5 258 270 6 1704,80 1704,81 99 2 
ADP/ATP translocase 1  P48962|ADT1_MOUSE     32901,27 9,73 13 24,8   
Transport 
  EQGFLSFWR Dioxidation(W)@8 64 72 14 1200,54 1200,56 99 1 
  QIFLGGVDR Gln->pyro-Glu@N-term 97 105 12 986,51 986,52 99 2 
  EQGFLSFWR Glu->pyro-Glu@N-term 64 72 9 1150,55 1150,56 99 2 
  GMGGAFVLVLYDEIK Oxidation(M)@2 281 295 7 1626,82 1626,83 99 2 
  GMGGAFVLVLYDEIKK Oxidation(M)@2 281 296 6 1754,92 1754,93 99 1 
  EQGFLSFWR Trp->Kynurenin(W)@8 64 72 6 1172,55 1172,56 99 1 
ATP synthase subunit alpha, mitochondrial Q03265|ATPA_MOUSE     59752,60 9,22 7 24,1   
OXPHOS 
  QGQYSPMAIEEQVAVIYAGVR Gln->pyro-Glu@N-term; Oxidation(M)@7 
473 493 
0 2307,12 2307,12 99 2 
Protein NipSnap homolog 2 O55126|NIPS2_MOUSE     32932,73 9,31 10 32   
unknown 
  KNQLLLEFSFWNEPVPR Dioxidation(W)@11 160 176 6 2148,09 2148,10 99 1 
  HGWEELVYYTVPLIQEMESR Dioxidation(W)@3; Oxidation(M)@17 251 270 0 2526,17 2526,17 99 1 
  ENQEFVNFR Glu->pyro-Glu@N-term 141 149 5 1163,53 1163,54 99 2 
  HGWEELVYYTVPLIQEMESR Oxidation(M)@17 251 270 0 2494,18 2494,18 99 2 
  KNQLLLEFSFWNEPVPR Trp->Kynurenin(W)@11 160 176 6 2120,09 2120,11 99 1 
Superoxide dismutase [Mn], mitochondrial P09671|SODM_MOUSE     24602,93 8,80 9 34,7   
Redox 
  FNGGGHINHTIFWTNLSPK Ammonia-loss(N)@2 90 108 7 2122,02 2122,04 99 2 
  AIWNVINWENVTER Dioxidation(W)@8 203 216 7 1774,85 1774,86 99 1 
  AIWNVINWENVTER Trp->Kynurenin(W)@3 203 216 12 1746,85 1746,87 99 1 
  AIWNVINWENVTER Trp->Kynurenin(W)@3; Dioxidation(W)@8 203 216 14 1778,83 1778,86 99 1 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 8, mitochondrial 
Q8K3J1|NDUS8_MOUSE     24038,33 5,89 11 37,7   
OXPHOS   LCEAICPAQAITIEAEPR Cys->Thr@6 118 135 31 1924,93 1924,99 99 2 
  LLNNGDKWEAEIAANIQADYLYR Deamidated(N)@4 190 212 -4 2680,32 2680,31 99 1 
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  LLNNGDKWEAEIAANIQADYLYR Deamidated(N)@4; Dioxidation(W)@8 190 212 -17 2712,35 2712,30 99 1 
  ILMWTELIR Dioxidation(W)@4 60 68 15 1205,63 1205,65 99 1 
  LLNNGDKWEAEIAANIQADYLYR Dioxidation(W)@8 190 212 5 2711,31 2711,32 99 1 
  ILMWTELIR Oxidation(M)@3 60 68 10 1189,64 1189,65 99 1 
Cytochrome c1, heme protein, mitochondrial  Q9D0M3|CY1_MOUSE     35327,64 9,24 7 27,1   
OXPHOS   AANNGALPPDLSYIVR Deamidated(N)@4 187 202 2 1670,86 1670,86 99 1 
  WASEPEHDHR FormaldehydeAdduct(W)@1 276 285 6 1274,53 1274,54 99 1 
ATP synthase subunit O, mitochondria Q9DB20|ATPO_MOUSE     23363,55 10,00 6 45,1   
OXPHOS 
  VSLAVLNPYIK Ile->Cys@10 74 84 9 1205,64 1205,65 99 2 
Cytochrome b-c1 complex subunit 2, mitochondrial  Q9DB77|QCR2_MOUSE     48234,9 9,26 7 17,7   
OXPHOS   LPNGLVIASLENYAPLSR Deamidated(N)@3 43 60 7 1927,03 1927,04 99 1 
  LPNGLVIASLENYAPLSR Pro->Ser@2 43 60 -2 1916,04 1916,04 99 2 
ES1 protein homolog, mitochondrial  Q9D172|ES1_MOUSE     28090,45 9,00 5 27,4   
unknown 
  GVEVTVGHEQEEGGKWPYAGTAEAIK Dioxidation(W)@16 187 212 1 2773,32 2773,32 99 1 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 10 O 
Q9DCS9|NDUBA_MOUSE     20892,61 8,36 5 17,6   
OXPHOS   AYDLVVDWPVTLVR Dioxidation(W)@8 36 49 8 1676,86 1676,88 99 1 
  AYDLVVDWPVTLVR Trp->Kynurenin(W)@8 36 49 11 1648,86 1648,88 99 1 
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial 
Q8BMF4|ODP2_MOUSE     58778,08 5,70 3 12,3   
Metabolism 
  LQPHEFQGGTFTISNLGMFGIK Oxidation(M)@18 548 569 1 2437,21 2437,209961 99 1 
Pyruvate dehydrogenase E1 component subunit 
alpha, somatic form, mitochondrial  
P35486|ODPA_MOUSE     43231,63 8,49 2 6,7   
Metabolism 
  LPCIFICENNR Cys->Dha(C)@3; Dioxidation(C)@7 216 226 24 1318,60 1318,63 99 2 
Electron transfer flavoprotein subunit beta  Q9DCW4|ETFB_MOUSE     27623,29 8,25 3 12,9   
Metabolism 
  GIHVEIPGAQAESLGPLQVAR Glu->Gln@5 86 106 56 2140,05 2140,18 99 2 
Heat shock cognate 71 kDa protein  P63017|HSP7C_MOUSE     70739,87 5,37 2 5,1   
Protein binding/folding 
  ATVEDEKLQGKINDEDKQK Asn->Arg@13 551 569 4 2229,15 2229,16 99 2 
3-hydroxyacyl-CoA dehydrogenase type-2  O08756|HCD2_MOUSE     27287,45 8,56 2 26,1   Metabolism 
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  LVAGEMGQNEPDQGGQR Oxidation(M)@6 131 147 7 1800,79 1800,81 99 2 
ADP/ATP translocase 2  P51881|ADT2_MOUSE     32931,29 9,74 8 28,5   
Transport 
  GAWSNVLR Dioxidation(W)@3 273 280 15 933,45 933,47 99 1 
  GMGGAFVLVLYDEIK Oxidation(M)@2 281 295 7 1626,82 1626,83 99 1 
  GMGGAFVLVLYDEIKK Oxidation(M)@2 281 296 6 1754,92 1754,93 99 1 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 3, mitochondrial 
Q9DCT2|NDUS3_MOUSE     30149,33 6,67 13 33,5   OXPHOS 
D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial 
Q80XN0|BDH_MOUSE     38284,97 9,14 4 17,2   Metabolism 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 9 
Q9CQJ8|NDUB9_MOUSE     21852,87 7,84 3 18,8   OXPHOS 
Myosin light chain 3 P09542|MYL3_MOUSE     22421,56 5,03 3 25   Structure 
Aconitate hydratase, mitochondrial  Q99KI0|ACON_MOUSE     85463,51 8,08 7 20,8   Metabolism 
Actin, alpha cardiac muscle 1  P68033|ACTC_MOUSE     42018,97 5,23 6 26   Structure 
Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial 
Q8K2B3|DHSA_MOUSE     72585,4 7,06 5 10,4   OXPHOS 
Trifunctional enzyme subunit alpha, mitochondrial  Q8BMS1|ECHA_MOUSE     82669,85 9,24 4 7,6   Metabolism 
Triosephosphate isomerase  P17751|TPIS_MOUSE     26581,43 7,09 4 19,3   Metabolism 
Metaxin-2  O88441|MTX2_MOUSE     29758,12 5,44 4 22,8   Transport 
Isocitrate dehydrogenase [NADP], mitochondrial  P54071|IDHP_MOUSE     50906,18 8,88 3 15,9   Metabolism 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 9, mitochondrial  
Q9DC69|NDUA9_MOUSE     42509,15 9,75 3 18,8   OXPHOS 
Cytochrome c oxidase subunit 4 isoform 1, 
mitochondrial  
P19783|COX41_MOUSE     19530,46 9,25 3 20,7   OXPHOS 
NADH dehydrogenase [ubiquinone] flavoprotein 1, 
mitochondrial  
Q91YT0|NDUV1_MOUSE     50834,2 8,51 3 11,6   OXPHOS 
Thioredoxin-dependent peroxide reductase, 
mitochondrial  
P20108|PRDX3_MOUSE     21564,58 5,73 3 10,1   Redox 
Malate dehydrogenase, mitochondrial  P08249|MDHM_MOUSE     35611,45 8,93 3 13,9   Metabolism 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 7, mitochondrial  
Q9DC70|NDUS7_MOUSE     24682,87 9,94 2 14,7   OXPHOS 
Mitochondrial inner membrane protein  Q8CAQ8|IMMT_MOUSE     83900,08 6,18 2 7,7   Signal transduction 
Phosphate carrier protein, mitochondrial  Q8VEM8|MPCP_MOUSE     34843,84 9,11 2 14,6   Transport 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 8  
Q9DCJ5|NDUA8_MOUSE     19860,88 8,80 2 24,4   OXPHOS 
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Citrate synthase, mitochondrial Q9CZU6|CISY_MOUSE     51736,67 8,72 2 9,3   Metabolism 
Voltage-dependent anion-selective channel protein 
3  
Q60931|VDAC3_MOUSE     30752,72 8,96 2 21,2   Transport 
Voltage-dependent anion-selective channel protein 
2  
Q60930|VDAC2_MOUSE     31732,84 7,44 2 13,2   Transport 
Tripartite motif-containing protein 72  Q1XH17|TRI72_MOUSE     52816,76 6,01 2 10,5   Transport 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 2, mitochondrial  
Q91WD5|NDUS2_MOUSE     52625,66 6,52 2 6,5   OXPHOS 
Cytochrome c, somatic  P62897|CYC_MOUSE     11605,44 9,61 2 23,8   OXPHOS 
Cytochrome c oxidase subunit 5A, mitochondrial  P12787|COX5A_MOUSE     12436,10 5,01 2 20,6   OXPHOS 
Fructose-bisphosphate aldolase A  P05064|ALDOA_MOUSE     39224,74 8,40 2 7,1   Metabolism 
Trifunctional enzyme subunit beta, mitochondrial  Q99JY0|ECHB_MOUSE     51386,34 9,43 1 11,4   Metabolism 
Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial  
Q61425|HCDH_MOUSE     34463,87 8,76 1 13,4   Metabolism 
Adenylate kinase isoenzyme 1  Q9R0Y5|KAD1_MOUSE     21539,60 5,67 1 23,2   Signal transduction 
Electron transfer flavoprotein subunit alpha, 
mitochondrial  
Q99LC5|ETFA_MOUSE     35009,44 8,62 1 14,7   Metabolism 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial 
Q9D2G2|ODO2_MOUSE     48994,52 9,10 1 15,2   Metabolism 
78 kDa glucose-regulated protein  P20029|GRP78_MOUSE     72422,06 5,07 1 7,6   Protein binding/folding 
Glutathione S-transferase Mu 1  P10649|GSTM1_MOUSE     25838,8 8,14 1 9,6   Redox 
Alpha-actinin-2 Q9JI91|ACTN2_MOUSE     103653,49 5,36 1 6,6   Structure 
Sarcalumenin  Q7TQ48|SRCA_MOUSE     99183,99 4,39 1 6,8   Signal transduction 
2,4-dienoyl-CoA reductase, mitochondrial  Q9CQ62|DECR_MOUSE     32451,38 8,78 1 12,8   Metabolism 
Calcium-binding mitochondrial carrier protein 
Aralar2  
Q9QXX4|CMC2_MOUSE     74466,93 8,77 1 2,8   Signal transduction 
Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial  
Q9D6R2|IDH3A_MOUSE     39638,71 6,27 1 4,9   Metabolism 
Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 3, mitochondrial  
Q9CRB9|CHCH3_MOUSE     26203,33 8,57 1 14,1   Structure 
ATP synthase subunit gamma, mitochondrial  Q91VR2|ATPG_MOUSE     30124,63 8,87 1 7   OXPHOS 
Acetyl-CoA acetyltransferase, mitochondrial  Q8QZT1|THIL_MOUSE     44816,12 8,71 1 6,4   Metabolism 
Ubiquinone biosynthesis protein COQ9, 
mitochondrial  
Q8K1Z0|COQ9_MOUSE     30240,70 4,93 1 10,5   
DNA/RNA/Protein 
biosynthesis 
NADH dehydrogenase [ubiquinone] 1 alpha Q7TMF3|NDUAC_MOUSE     17086,41 9,38 1 22,8   OXPHOS 
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subcomplex subunit 12  
60S ribosomal protein L10 Q6ZWV3|RL10_MOUSE     24472,7 10,11 1 9,3   
DNA/RNA/Protein 
biosynthesis 
Prohibitin P67778|PHB_MOUSE     29820,10 5,57 1 7,7   
DNA/RNA/Protein 
biosynthesis 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 6, mitochondrial  
P52503|NDUS6_MOUSE     10777,04 6,64 1 12,1   OXPHOS 
3,2-trans-enoyl-CoA isomerase, mitochondrial  P42125|D3D2_MOUSE     29110,72 7,77 1 9   Metabolism 
Stress-70 protein, mitochondrial  P38647|GRP75_MOUSE     73528,33 5,91 1 4,6   Protein binding/folding 
Glutathione S-transferase P 1  P19157|GSTP1_MOUSE     23477,99 8,13 1 12,9   Redox 
Aspartate aminotransferase, mitochondrial  P05202|AATM_MOUSE     44579,04 8,97 1 5,6   Metabolism 
Myosin-binding protein C, cardiac-type  O70468|MYPC3_MOUSE     140632,49 6,06 1 2,3   Signal transduction 
Mitochondrial carnitine/acylcarnitine carrier protein  Q9Z2Z6|MCAT_MOUSE     33026,74 9,24 1 2,7   Transport 
Cytochrome b-c1 complex subunit 7  Q9D855|QCR7_MOUSE     13396,28 9,10 1 9   OXPHOS 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 6 
Q9CQZ5|NDUA6_MOUSE     15282,80 10,10 1 8,4   OXPHOS 
MACRO domain-containing protein 1 Q922B1|MACD1_MOUSE     35294,69 9,07 1 7,1   unknown 
Electron transfer flavoprotein-ubiquinone 
oxidoreductase, mitochondrial  
Q921G7|ETFD_MOUSE     68090,93 7,34 1 1,8   Metabolism 
Lon protease homolog, mitochondrial  Q8CGK3|LONM_MOUSE     98861,48 5,69 1 0,9   Proteolysis 
Enoyl-CoA hydratase, mitochondrial  Q8BH95|ECHM_MOUSE     28474,72 7,78 1 7,2   Metabolism 
Dapper homolog 2  Q7TN08|DACT2_MOUSE     11710,21 11,20 1 2   Signal transduction 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 4  
Q62425|NDUA4_MOUSE     9326,79 9,52 1 14,6   OXPHOS 
5 x x x 
ATP synthase subunit d, mitochondrial    Q9DCX2|ATP5H_MOUSE     18749,45 5,52 29 80,1   OXPHOS 
Cytochrome b-c1 complex subunit 1, mitochondrial  Q9CZ13|QCR1_MOUSE     52768,7 5,75 15 43,3 
 
OXPHOS 
NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial  
Q9D6J6|NDUV2_MOUSE     27285,34 7,00 12 65,3   OXPHOS 
ATP synthase subunit O, mitochondrial Q9DB20|ATPO_MOUSE     23363,55 10,00 12 71,8   OXPHOS 
ATP synthase subunit b, mitochondrial  Q9CQQ7|AT5F1_MOUSE     28948,83 9,11 8 39,5   OXPHOS 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 9  
Q9CQJ8|NDUB9_MOUSE     21852,87 7,84 8 48,6   OXPHOS 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 10  
Q9DCS9|NDUBA_MOUSE     20892,61 8,36 9 47,7   OXPHOS 
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Mitochondrial 2-oxoglutarate/malate carrier protein  Q9CR62|M2OM_MOUSE     34023,00 9,95 5 24,8   Transport 
Cytochrome b-c1 complex subunit Rieske, 
mitochondrial  
Q9CR68|UCRI_MOUSE     34023,71 9,95 7 43,8   OXPHOS 
Protein NipSnap homolog 2 O55126|NIPS2_MOUSE     32932,73 9,31 5 30,3   unknown 
ATP synthase subunit beta, mitochondrial  P56480|ATPB_MOUSE     55262,41 5,24 4 31,8   OXPHOS 
Cytochrome c oxidase subunit 2  P00405|COX2_MOUSE     25976,4 4,60 15 44,1   OXPHOS 
ADP/ATP translocase 1  P48962|ADT1_MOUSE     32904,27 9,73 4 24,5   Transport 
Superoxide dismutase [Mn], mitochondrial  P09671|SODM_MOUSE     24602,93 8,80 16 48,2   Redox 
Thioredoxin-dependent peroxide reductase, 
mitochondrial  
P20108|PRDX3_MOUSE     21564,58 5,73 4 22,6   Redox 
Creatine kinase S-type, mitochondrial  Q6P8J7|KCRS_MOUSE     47473,32 8,64 3 19,6   Signal transduction 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 8, mitochondrial  
Q8K3J1|NDUS8_MOUSE     24038,33 5,89 10 41,5   OXPHOS 
Cytochrome c1, heme protein, mitochondrial  Q9D0M3|CY1_MOUSE     35327,64 9,24 4 24,9   OXPHOS 
Ferritin light chain 1  P29391|FRIL1_MOUSE     20671,2 5,66 2 25,7   Redox 
Cytochrome c oxidase subunit 4 isoform 1, 
mitochondrial  
P19783|COX41_MOUSE     19530,46 9,25 2 24,9   OXPHOS 
Aconitate hydratase, mitochondrial  Q99KI0|ACON_MOUSE     85463,51 8,08 2 22,4   Metabolism 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 3, mitochondrial 
Q9DCT2|NDUS3_MOUSE     30149,33 6,67 2 12,2   OXPHOS 
ES1 protein homolog, mitochondrial  Q9D172|ES1_MOUSE     28090,45 9,00 2 19,9   unknown 
Adenylate kinase isoenzyme 1  Q9R0Y5|KAD1_MOUSE     21539,6 5,67 1 38,1   Signal transduction 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 8, mitochondrial  
Q9D6J5|NDUB8_MOUSE     21875,83 6,15 2 21   OXPHOS 
Isocitrate dehydrogenase [NADP], mitochondrial  P54071|IDHP_MOUSE     50906,18 8,88 1 14,6   Metabolism 
Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial  
Q9D6R2|IDH3A_MOUSE     39638,71 6,27 1 21,9   Metabolism 
Myosin-7 Q91Z83|MYH7_MOUSE     222878,85 5,59 1 15,2   Structure 
Actin, cytoplasmic 2 P63260|ACTG_MOUSE     41792,84 5,31 1 9,9   Structure 
Malate dehydrogenase, mitochondria P08249|MDHM_MOUSE     35611,45 8,93 1 9,5   Metabolism 
Succinate dehydrogenase [ubiquinone] iron-sulfur 
subunit, mitochondrial  
Q9CQA3|DHSB_MOUSE     31813,9 8,96 1 29,8   OXPHOS 
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Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial  
Q8BMF4|ODP2_MOUSE     58778,08 5,70 1 13,2   Metabolism 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 12  
Q7TMF3|NDUAC_MOUSE     17086,41 9,38 1 37,2   OXPHOS 
Acyl-protein thioesterase 1  P97823|LYPA1_MOUSE     24687,69 6,14 1 13,9   Metabolism 
Cytochrome c, somatic  P62897|CYC_MOUSE     11605,44 9,61 1 41,9   OXPHOS 
Cytochrome b-c1 complex subunit 2, mitochondrial  Q9DB77|QCR2_MOUSE     48234,9 9,26 1 9,7   OXPHOS 
60S ribosomal protein L10 Q6ZWV3|RL10_MOUSE     24472,7 10,11 1 19,6   
DNA/RNA/Protein 
biosynthesis 
Voltage-dependent anion-selective channel protein 
1  
Q60932|VDAC1_MOUSE     32351,49 8,55 1 11,2   Transport 
Electron transfer flavoprotein-ubiquinone 
oxidoreductase, mitochondrial 
Q921G7|ETFD_MOUSE     68090,93 7,34 1 5,7   Metabolism 
Mitochondrial inner membrane protein  Q8CAQ8|IMMT_MOUSE     83900,08 6,18 2 13,7   Signal transduction 
Isocitrate dehydrogenase [NAD] subunit gamma 1, 
mitochondrial  
P70404|IDHG1_MOUSE     42785,44 9,17 1 8,7   Metabolism 
ATP synthase subunit alpha, mitochondrial  Q03265|ATPA_MOUSE     59752,6 9,22 1 5,2   Metabolism 
Pyruvate dehydrogenase E1 component subunit 
alpha, somatic form, mitochondrial  
P35486|ODPA_MOUSE     43231,63 8,49 2 20,5   Metabolism 
Lon protease homolog, mitochondrial  Q8CGK3|LONM_MOUSE     98861,48 5,69 1 9,1   Proteolysis 
D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial  
Q80XN0|BDH_MOUSE     38284,97 9,14 2 12,8   Metabolism 
Long-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
P51174|ACADL_MOUSE     47907,95 8,53 1 12,6   Metabolism 
Transmembrane protein 126A  Q9D8Y1|T126A_MOUSE     21539,22 9,45 1 23   Structure 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 4, mitochondrial  
Q9CXZ1|NDUS4_MOUSE     19784,69 10,00 1 10,3   OXPHOS 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 8  
Q9DCJ5|NDUA8_MOUSE     19860,88 8,80 1 26,7   OXPHOS 
40S ribosomal protein SA  P14206|RSSA_MOUSE     32706,89 4,80 1 9,8 
 
DNA/RNA/Protein 
biosynthesis 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 7, mitochondrial  
Q9DC70|NDUS7_MOUSE     24682,97 9,94 1 13,4   OXPHOS 
6 x x x 
Cytochrome c oxidase subunit 5A, mitochondrial  
 
P12787|COX5A_MOUSE     12436,1 5,01 25 58,9   OXPHOS 
Cytochrome c oxidase subunit 5B, mitochondrial  P19536|COX5B_MOUSE     10718,18 5,74 10 44,5   OXPHOS 
Cytochrome b-c1 complex subunit 7  Q9D855|QCR7_MOUSE     13396,28 9,10 5 52,3   OXPHOS 
 
 
199 
Cytochrome c, somatic  P62897|CYC_MOUSE     11605,44 9,61 10 60   OXPHOS 
ATP synthase subunit beta, mitochondrial  P56480|ATPB_MOUSE     11605,44 9,61 5 28,5   OXPHOS 
Fatty acid-binding protein, heart  P11404|FABPH_MOUSE     14687,66 6,15 8 36,8   Metabolism 
ADP/ATP translocase 1  P48962|ADT1_MOUSE     32904,27 9,73 7 23,5   Transport 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 6  
Q9CQZ5|NDUA6_MOUSE     15282,8 10,10 3 43,5   OXPHOS 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 6, mitochondrial  
P52503|NDUS6_MOUSE     10777,04 6,64 3 34,5   OXPHOS 
ATP synthase subunit delta, mitochondrial  Q9D3D9|ATPD_MOUSE     15023,87 4,46 3 22,6   OXPHOS 
Cytochrome c oxidase subunit 6A2, mitochondrial P43023|CX6A2_MOUSE     9421,68 8,13 3 38,1   OXPHOS 
Cytochrome c oxidase subunit 6A1, mitochondrial  P43024|CX6A1_MOUSE     9619,83 6,63 2 41,4   OXPHOS 
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 5  
Q99LY9|NDUS5_MOUSE     12516,49 9,12 2 25,5   OXPHOS 
Cytochrome c oxidase subunit 6C  Q9CPQ1|COX6C_MOUSE     8337,81 10,13 2 34,2   OXPHOS 
NADH dehydrogenase [ubiquinone] 1 subunit C2  Q9CQ54|NDUC2_MOUSE     14163,66 9,24 1 22,5   OXPHOS 
Cytochrome b-c1 complex subunit 8  Q9CQ69|QCR8_MOUSE     9637,06 10,26 1 29,3   OXPHOS 
Enoyl-CoA hydratase, mitochondrial  Q8BH95|ECHM_MOUSE     28474,72 7,78 1 16,2   Metabolism 
Acyl-coenzyme A thioesterase 13  Q9CQR4|ACO13_MOUSE     15182,84 8,95 1 18,6   Metabolism 
Aconitate hydratase, mitochondrial  Q99KI0|ACON_MOUSE     85463,51 8,08 1 4   Metabolism 
Mitochondrial carrier homolog 2  Q791V5|MTCH2_MOUSE     33367,92 8,60 1 9,6   Transport 
Voltage-dependent anion-selective channel protein 
1  
Q60932|VDAC1_MOUSE     32351,49 8,55 1 11,5   Transport 
Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
P50544|ACADV_MOUSE     70875,5 8,91 1 3,7   Metabolism 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 7 
Q9Z1P6|NDUA7_MOUSE     12444,39 10,17 1 9,7   OXPHOS 
Microsomal glutathione S-transferase 3  Q9CPU4|MGST3_MOUSE     16957,77 9,54 1 9,2   Redox 
ATP synthase subunit g, mitochondrial  Q9CPQ8|ATP5L_MOUSE     11293,32 9,74 1 18,5   OXPHOS 
Trifunctional enzyme subunit beta, mitochondrial  Q99JY0|ECHB_MOUSE     51386,34 9,43 1 2,3   Metabolism 
CDGSH iron-sulfur domain-containing protein 1 O Q91WS0|CISD1_MOUSE     12096,96 9,17 1 12   Signal transduction 
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NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 4  
Q62425|NDUA4_MOUSE     9326,79 9,52 1 14,6   OXPHOS 
ATP synthase subunit e, mitochondrial  Q06185|ATP5I_MOUSE     8104,41 9,35 1 9,9   OXPHOS 
ADP/ATP translocase 2 P51881|ADT2_MOUSE     32931,29 9,74 3 18,8   Transport 
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STUDY II - OXPHOS SUSCEPTIBILITY TO OXIDATIVE MODIFICATIONS: THE 
ROLE OF HEART MITOCHONDRIAL SUBCELLULAR LOCATION 
 
 
 
 
 
   
Supplementary Figure S1: Comparison of relative quantities of ATP synthase subunit β in cardiac 
mitochondrial populations determined by Western blotting analysis. A representative panel of 
immunoblot is presented above the histogram. Results represent the mean ± SEM for five pools of 
IMF and SS fractions 
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STUDY III - IMPAIRED PROTEIN QUALITY CONTROL SYSTEM UNDERLIES 
MITOCHONDRIAL DYSFUNCTION IN SKELETAL MUSCLE OF STREPTOZOTOCIN-
INDUCED DIABETIC RATS 
 
 
 
Supplementary Figure S1: Representative TEM micrographs of IMF mitochondria isolated from 
CONT (A) and T1DM (B) gastrocnemius muscle. 
 
 
 
 
Supplementary Figure S2: Representative profile of Ponceau S stained western (A) and slot (B) 
blots. 
 204 
 
 
 
Supplementary Figure S3: Lon protease sequence (accession #LONM_RAT) evidencing the 
domains (underlined) assigned according toMEROPS with the identified peptides annotated: in red 
the ones identified in band 1, in blue boxes the ones observed in band 5 and in green boxes the 
peptides identified in band 6.  
 
 
Supplementary Figure S4:  MS/MS spectrum of the peptide 371EGWPLDIR378 derived from 
tryptic digestion of aconitate hydratase (accession #ACON_RAT) containing a pyro-Glu@N-term 
(annotated as pyroE), which analysis was performed following the methodological approach 
previously described [33]. The b and y ion series are annotated.   
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STUDY IV - BLADDER CANCER-INDUCED CACHEXIA: DISCLOSING THE ROLE 
OF MITOCHONDRIA PLASTICITY IN SKELETAL MUSCLE WASTING 
 
 
 
 
 
Supplementary Figure S1: Food intake over the course of the experimental protocol. 
  
 
Supplementary Figure S2:  Separation of mitochondrial proteins by 12 5% SDS-PAGE 
(considering sample volumes and protein content). 
 
